

CURRICULUM VITAE

Laurent Brard, M.D., Ph.D., F.A.C.O.G.

PERSONAL INFORMATION

Work Address: Department Obstetrics and Gynecology, SIU School of Medicine, 415 N. 9th St. Suite 6W70, PO Box 19640, Springfield, IL 62794-9640

Work Telephone: (217) 545-8882

Work E-Mail: lbrard@siumed.edu

Personal E-Mail: lbrardius@gmail.com

EDUCATION

Sep 1984 - Jul 1987 École Supérieure de Chimie Industrielle de Lyon, Villeurbanne, France, B.Sc. (Chemical Engineering)

Sep 1986 - Aug 1987 Université Claude Bernard Lyon 1, Villeurbanne, France
M.Sc. (Organic Chemistry)

Sep 1987 - Dec 1991 Northwestern University (Department of Chemistry), Evanston, Illinois, Ph.D. (Chemistry) – Degree Awarded in June 1992

Jan 1992 - Sep 1992 Northwestern University (Department of Chemistry), Evanston, Illinois, Post-Doctoral Fellow (Chemistry)

Oct 1992 - Jul 1994 University of Pennsylvania (Department of Chemistry), Philadelphia, Pennsylvania, Post-Doctoral Fellow (Chemistry-Material Science)

Aug 1994 - May 1998 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.D. degree)

POSTGRADUATE TRAINING

Jun 1998 - Jun 1999 Internship, Obstetrics and Gynecology
Women & Infants Hospital / Brown University, Providence, RI

Jul 1999 - Jun 2002 Residency, Obstetrics and Gynecology
Women & Infants Hospital / Brown University, Providence, RI

Jul 2002 - Jun 2005 Fellowship, Gynecologic Oncology
Women & Infants Hospital / Brown University, Providence, RI

POSTGRADUATE HONORS AND AWARDS

1987-1991 Rhône-Poulenc Pre-Doctoral Scholarship Award

1988-1991 Phi Lambda Upsilon (Honors Society)

1992 AKZO Post-Doctoral Scholarship Award

1997-1998	Robert E. Lee, M.D. Excellence in Anatomic Pathology Award
1998-2005	Excellence in Teaching Award (Brown Medical School)
1999	Ortho-McNeil CREOG Award (Outstanding Performance)
1999-2000	Top Resident Teacher of the Year Award (Women & Infants Hospital)
1999-2000	Berlex Best Teaching Resident Award
2000-2002	Dean's Teaching Excellence Award (Brown Medical School)
2001-2002	Top Resident Teacher of the Year Award (Women & Infants Hospital)
2001-2002	Research Project Certificate of Completion Award
2001-2002	Excellence in Resident Research Award
2001-2002	David H. Nichols, M.D. Award for Excellence in Pelvic Surgery
2002-2003	Top Fellow Teacher of the Year Award (Women & Infants Hospital)
2003	Top Research Paper / Presentation (23 rd New England Association of Gynecologic Oncologist Annual Meeting)
2003-2004	APGO / Organon Medical Education Research Award
2003-2004	Excellence in Fellow Teaching Award (Women & Infants Hospital)
2004-2005	Dean's Teaching Excellence Award (Brown Medical School)
2004-2005	Top Fellow Teacher of the Year Award (Women & Infants Hospital)
2005-2006	Dean's Teaching Excellence Award (Brown Medical School)
2005-2006	Top Full Time Faculty Teacher Award (Women & Infants Hospital)
2007-2008	Excellence in Resident Teaching Award (Women & Infants Hospital)
2008	Fellow of The American College of Obstetricians and Gynecologists
2017	CREOG National Faculty Award for Excellence in Resident Education

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Illinois, #036127342, exp. 07/31/2020

Rhode Island, #MD10986, exp. 6/30/2018

Connecticut, #044200, exp. 12/31/2017

Massachusetts, #216975, exp. 12/03/2018

Board Certified **Obstetrics and Gynecology** (11/10/2006); Re-certified 07/2012, 09/2013, 04/2014, 09/2015, 08/2016, 08/2017

Board Certified **Gynecologic Oncology** (04/16/2015); Re-certified 08/2016, 08/2017

EMPLOYMENT

Jun 1998 - Jun 30, 2010	Women & Infants Hospital, 101 Dudley Street, Providence, RI 02905
Jul 2010 - Dec 2010	Interviewing for Gynecologic Oncology Faculty Positions
Dec 2010 - Present	SIU School of Medicine and SIU Healthcare, Dept. OB/GYN, 415 N. 9th Street Ste. 6W70 Springfield, IL 62702

ACADEMIC APPOINTMENTS

Sep 1987 - Jun 1990	Instructor, Sophomore Chemistry Northwestern University, Evanston, IL
Jun 2001 - Jun 2002	Assistant Instructor, Obstetrics and Gynecology Brown University, Providence, RI
Jul 2002 - Jun 2003	Research and Teaching Fellow, Gynecologic Oncology Brown University, Providence, RI
Jul 2003 - Jun 2005	Teaching Fellow, Gynecologic Oncology Brown University, Providence, RI
Jul 2005 - Sep 2008 and Jan 2009 - Jun 2010	Assistant Professor, Obstetrics and Gynecology Alpert Medical School of Brown University, Providence, RI
Dec 2010 - Mar 2011	Associate Professor of Clinical Obstetrics and Gynecology/Research SIU School of Medicine, Springfield, IL
Apr 2011 - Dec 2012	Associate Professor of Obstetrics and Gynecology Division of Gynecologic Oncology Department of Obstetrics and Gynecology SIU School of Medicine, Springfield, IL
Jan 2013 – Jun 2017	Associate Professor of Obstetrics and Gynecology Chief, Division of Gynecologic Oncology Department of Obstetrics and Gynecology SIU School of Medicine, Springfield, IL
Jul 2017 - Present	Professor (with Tenure) of Obstetrics and Gynecology Chief, Division of Gynecologic Oncology Department of Obstetrics and Gynecology SIU School of Medicine, Springfield, IL

OTHER ACADEMIC APPOINTMENTS/COMMITTEES

Jul 2002 - Jun 2003	Clinical Instructor and Research Investigator University of Rhode Island, South Kingston, RI
Nov 2005 - Apr 2007	Co-Director, Program in Women's Oncology at Landmark Medical Center, Woonsocket, RI
Nov 2005 - Jun 2010	Director, Molecular Therapeutics Laboratory, Program in Women's Oncology Kilguss Research Building, Women & Infants Hospital, Providence, RI
Dec 2010 - Present	Director, Division of Gynecologic Oncology Research Laboratory, SIU School of Medicine, Springfield, IL

Jan 2011 - Present	Full Member, Simmons Cancer Institute, SIU School of Medicine, Springfield, IL
May 2011 - Present	Member of SIU HealthCare, Springfield, IL
Nov 2011 - Nov 2012	Member, Conflict of Interest Committee, SIU School of Medicine, Springfield, IL
Mar 2013 - Present	Member, Tissue Bank Committee, Simmons Cancer Institute, SIU School of Medicine, Springfield, IL
Jun 2013 - Present	Full Member, SCRIHS (Institutional Review Board), SIU School of Medicine, Springfield, IL
Jul 2014 - Present	2 nd Vice-Chair, SCRIHS (Institutional Review Board), SIU School of Medicine, Springfield, IL
Jul 2014 - Present	Member, Advisory Panel, SCRIHS (Institutional Review Board), SIU School of Medicine, Springfield, IL
Jul 2014 - Present	Member, OBGYN Residency Evaluation Committee, SIU School of Medicine, Springfield, IL
2015	Member, Chair of Internal Medicine Search Committee
2015-2016	Member, Research Strategic Planning Committee
June 2016	Member, Associate Dean of Research Search Committee
July 2017 - Present	Member, Promotion and Tenure Committee, Department of Obstetrics and Gynecology, SIU School of Medicine, Springfield, IL

CURRENT HOSPITAL APPOINTMENTS

May 2011 - Present	Active Staff with Admitting, Gynecologic Oncologist Memorial Medical Center, Springfield, IL
Jul 2011 - Present	Active Associate Staff with Admitting, Gynecologic Oncologist SHS St. John's Hospital, Springfield, IL

PAST HOSPITAL APPOINTMENTS

Jul 2005 - Jul 2008	Active Staff with Admitting, Gynecologic Oncologist
Nov 2008 - Apr 2010	Women & Infants Hospital, Providence, RI
Nov 2005 - Jun 2009	Courtesy Staff, Gynecologic Oncologist Landmark Medical Center, Woonsocket, RI
Nov 2005 - Sep 2008	Active Staff with Admitting, Gynecologic Oncologist The Miriam Hospital, Providence, RI
Dec 2005 - Sep 2008	Active Staff with Admitting, Gynecologic Oncologist
Sep 2009 - Apr 2010	Rhode Island Hospital, Providence, RI
Mar 2006 - Aug 2010	Consulting Staff, Gynecologic Oncologist South County Hospital, Wakefield, RI
Jun 2007 - Jun 2010	Supplemental Staff, Gynecologic Oncologist Kent Hospital, Warwick, RI

Jun 2007 - Sep 2008	Courtesy Staff, Gynecologic Oncologist Newport Hospital, Newport, RI
Jul 2008 - Apr 2010	Courtesy Staff, Gynecologic Oncologist Roger Williams Hospital, Providence, RI
Jan 2006 - Sep 2009	Affiliate Staff, Gynecologic Oncologist Sturdy Memorial Hospital, Attleboro, MA
Apr 2006 - Feb 2009	Courtesy Staff, Gynecologic Oncologist Milford Regional Medical Center, Milford, MA
Apr 2006 - Sep 2009	Affiliate Staff, Gynecologic Oncologist St. Luke's Hospital, New Bedford, MA
Oct 2006 - Sep 2009	Affiliate Staff, Gynecologic Oncologist Charlton Memorial Hospital, Fall River, MA
May 2007 - Dec 2008	Consulting Staff, Gynecologic Oncologist Falmouth Hospital, Falmouth, MA
Jun 2007 - Jun 2010	Visiting Consulting Staff, Gynecologic Oncologist Lawrence & Memorial Hospital, New London, CT
Oct 2012 - Oct 2014	Medical Director, Oncology Service Line SHS St. John's Hospital, Springfield, IL

HOSPITAL COMMITTEES

Jul 2005 - Jul 2008 Jan 2009 - Apr 2010	Chair, Gynecologic Oncology Prospective Tumor Board Women & Infants Hospital, Providence, RI
Sep 2005 - Jul 2008	Chair, Pain Management Committee Women & Infants Hospital, Providence, RI
Jun 2006 - Sep 2008 Sep 2009 - Apr 2010	Member, Acute Monitoring Services Committee Women & Infants Hospital, Providence, RI
Jun 2009 - Apr 2010	Member, Quality Council Medical/Surgical unit Women & Infants Hospital, Providence, RI
Oct 2009 - Apr 2010	Member, Acute Response Team Women & Infants Hospital, Providence, RI
Dec 2011 - Present	Member, Robotic Committee Memorial Medical Center, Springfield, IL
Dec 2011 - Present	Member, Surgical Case and Procedure Review (Tissue) Committee Memorial Medical Center, Springfield, IL
Oct 2012 - Jul 2013	SIU School of Medicine - St. John's Hospital Co-Management Committee SHS St. John's Hospital, Springfield, IL
Nov 2015 - Present	Member, WCC Service Council SHS St. John's Hospital, Springfield, IL
Sep 2017 - Jan 2018	Member, OR Governance Committee SHS St. John's Hospital, Springfield, IL

Jan 2018 – Present Chair, OR Governance Committee
 HSHS St. John's Hospital, Springfield, IL

NATIONAL COMMITTEES/RESPONSIBILITIES

2009 **Scientific Review Panel Member** for NIH/NCI ZRG1 ONC-Z(13)B, Cancer Therapeutics Discovery and Development Treatment, Oncological Sciences Small Business Activities [SBIR/STTR], March 4-5, 2009.

2009 **Scientific Review Panel Member** for NIH/NCI ZRG1 OTC-K(58) R Special Emphasis Panel, July 20-21, 2009.

2009 **Reviewer**, Abstracts for the SGO 41st Annual Meeting on Women's Cancer October 16-26, 2009

2009 - 2010 **Committee Member**, Experimental Medicine, Gynecologic Oncology Group (GOG)

2010 **Scientific Review Panel Member** for 2010/05 ZCA1 SRLB-C (M1) B, NIH/EDRN Biomarker Development Labs (U01) Panel, May 10-11, 2010.

2010 **Scientific Review Panel Member** for CDMRP Ovarian Cancer Basic Sciences (BSC) Panel, July 25-27, 2010.

2011 **Scientific Review Panel Member** for 2011/10 NCI-F Subcommittee F - Manpower & Training, June 28-29, 2011.

2014 - 2015 **Principal Investigator for NRG Oncology Affiliate Site** (site IL095 and RTOG site 2115), July 14, 2014-December 31, 2015.

2017 **Special Emphasis Panel/Scientific Review Group** for NIH 2017/08 ZCA1 PCRB-B (A1), May 5, 2017.

MEMBERSHIP IN SOCIETIES

1992 - 2014 American Chemical Society

1994 - 1998 American Medical Student Association

1994 - Present American Medical Association

1998 - 2008 The American College of Obstetricians and Gynecologists (Junior Fellow)

2002 - Present The Society of Gynecologic Oncologists

2003 - 2010 The Rhode Island Medical Society

2006 - Present American Society of Clinical Oncologists

2006 - 2009 American Association for the Advancement of Science

2008 - Present The American College of Obstetricians and Gynecologists (Fellow)

2009 - Present American Association for Cancer Research

2011 - Present Central Illinois Community Clinical Oncology Program (CICCOP)

2013 - Present NRG Oncology

2015 - Present American Society of Preventive Oncology

JOURNAL REVIEWER *ad hoc*

2006 - Present	Gynecologic Oncology
2006 - Present	Cell Biology International
2006 - Present	European Journal of Clinical Nutrition
2007 - Present	Journal of Pharmacology and Experimental Therapeutics
2007 - Present	Medicinal Chemistry Research
2007 - Present	European Journal of Medicinal Chemistry
2008 - Present	Food Chemistry
2008 - Present	Molecular Nutrition and Food Research
2008 - Present	American Journal of Obstetrics and Gynecology
2008 - Present	Chemical Biology & Drug Design
2009 - Present	Cancer Letters
2010 - Present	European Journal of Pharmacology
2010 - Present	Current Drug Delivery

UNIVERSITY TEACHING/MENTORING ROLES**SIU School of Medicine Faculty Mentoring**

1. **Paula L. Diaz-Sylvester, PhD.** Research Assistant Professor, Center for Clinical Research and Department of OBGYN (July 2016 - present). Mentor on NIH R50 application titled: Rural Cancer Disparities and Biomarker Discoveries and P4 application (funding mechanism derived from the NIH/NCI P20CA192987 grant) titled: Exploring Modifiable Factors Associated with Advanced Stage Gynecologic Cancers in Geographical "Hot Spots".

SIU School of Medicine Obstetrics and Gynecology Medical Student Teaching/Lecturing

1. Medical student education during OBGYN clerkship on Gynecologic Oncology Topics (Feb 2011- present).
2. Medical student 3/4th year elective in Gynecologic Oncology (elective director) – (2012 - present).
 - a. **Codi Williams**, SIUSM (2012-2013)
 - b. **Daniel Ryan**, SIUSM (2013-2014)
 - c. **Kathyryne Sanserino**, SIUSM (2013-2014)
 - d. **Elena Stuewe**, SIUSM (2014-2015)
 - e. **Rachel Zilles**, Western University of Health Sciences (2015-2016)
3. Medical student (2nd year) lecture on ovarian neoplasms (yearly lecture) – (2014 - 2016)
4. Medical student (2nd year) Selective
 - a. **Andrea Ulysse**, (Apr 2013)
 - b. **Karen Philabaun**, (Apr 2013)
 - c. **Emily Perkins**, (Apr 2013)
 - d. **Jaleen Sims**, (Mar 2013)
 - e. **Elena Stuewe**, (May 2014)
 - f. **Cindy Gregory**, (May 2014)
 - g. **Gerald Miller**, (Apr 2014)
 - h. **Justine Nuguid**, (Mar 2014)

- i. **Markesha Jones**, (May 2015)
 - j. **Aishah Yanssaneh**, (May 2015)
 - k. **Jenna Goeckner**, (Apr 2015)
 - l. **Jeala Barnett**, (Apr 2015)
 - m. **Daniel Summers**, (Apr 2015)
 - n. **Rachel Segal**, (Mar 2015)
 - o. **Brittany Koch**, (Mar 2015)
 - p. **Christine Goehl**, (Mar 2016)
 - q. **Kyley Maxheimer**, (Mar 2016)
 - r. **Dakota Gilbert**, (Mar 2016)
 - s. **Jennifer Brown**, (Mar 2016)
 - t. **Daniel Boeder**, (Apr 2016)
 - u. **Alexandra Barger**, (Apr 2016)
 - v. **Laura Endris**, (Apr 2016)
 - w. **Mackenzie Mattern**, (Mar 2017)
 - x. **Madelyn Fetter**, (Mar 2017)
 - y. **Mackenzie Mattern**, (Apr 2017)
5. Resident Readiness Elective - Cadaver Lab (Apr 2011, Mar 2012, Apr 2016, Mar 2017)

SIU School of Medicine Resident Teaching/Lecturing

- 1. OBGYN resident education on Gynecologic Oncology Topics (Jan 2011 - present).
- 2. Family Medicine resident education in Gynecologic Oncology Clinic (Aug 2013 - present).
 - a. **Kelly Luciano, MD** (Aug 2013)
 - b. **Stephanie Gadbois, MD** (Sep 2013)
 - c. **Angela Recaurte, MD** (Dec 2013)
 - d. **Aishah Covington-Simms, MD** (Feb 2014)
 - e. **Sung Jang, MD** (Apr 2014)
 - f. **Uzma Jalal, MD** (June 2014)
 - g. **Sriveer Kaasam, MD** (Oct 2014)
 - h. **Tazeen Al-Haq, MD** (Dec 2014)
 - i. **Imad Aziz, MD** (Jan 2015)
 - j. **Noureen Zohra, MD** (Mar 2015)
 - k. **Ashley McDonald, DO** (Apr 2015)
 - l. **Marcin Jungiewicz, MD** (May 2015)
 - m. **Eva Ratajczak, MD** (Aug 2015)
 - n. **Carlos Avila, MD** (Nov 2015)
 - o. **Sandya Shivashankar, MD** (Jan 2016)
 - p. **Supriya Gupta, MD** (Feb 2016)
 - q. **Michael Owolabi, MD** (Mar 2016)
 - r. **Bright Ohene Odei, MD** (Jun 2016)
 - s. **Jennifer Schuerm, MD** (Sep 2016)
 - t. **Farid Zahedieh, MD** (Oct 2016)
 - u. **Deepa Gurusamy, MD** (Nov 2016)
 - v. **Solmaz Bauk, MD** (Dec 2016)
 - w. **Daesson Leem, MD** (Jan 2017)
 - x. **Kathryn Buffey, DO** (Feb 2017)
 - y. **Namrata Singhi, MD** (Apr 2017)
 - z. **Alecia Altheimer, MD** (May 2017)
 - aa. **Waiz Wasey, MD** (Jun 2017)
 - bb. **Priyanka Bhandari, MD** (Jul 2017)
 - cc. **Amanda Krus, DO** (Aug 2017)
 - dd. **Natalie Mahoney, MD** (Sep 2017)
 - ee. **William Bailey, MD** (Oct 2017)
 - ff. **Sam Fatoorehchi, MD** (Nov 2017)

gg. **Salman Saeed, MD** (February 2018)

TEACHING IN HOSPITAL SETTINGS

Brown University Medical Student Teaching - BioMed 495 - Gyn Oncology & Pelvic Surgery

1. Medical student education on Gynecologic Oncology Rotations (Jul 2005 - Jul 2008, Jan 2009 - Apr 2010).

SIU School of Medicine Medical Student Teaching - Course #50223 - Gyn Oncology Elective

1. Medical student education on Gynecologic Oncology Rotation (Jul 2012 - present).

Brown University Obstetrics and Gynecology Resident Teaching

1. Resident education on Gynecologic Oncology Rotations (Jul 2005 - Jul 2008, Jan 2009 - Apr 2010).

SIU School of Medicine Obstetrics and Gynecology Resident Teaching

1. Resident education on Gynecologic Oncology Rotations (May 2011 - present).

Brown University Gynecologic Oncology Fellow Teaching

1. **Antonella Restivo, MD**. Inpatient, outpatient care and operating room techniques (Jul 2005 - Jun 2007).
2. **Carolyn McCourt, MD**. Inpatient, outpatient care and operating room techniques (Jul 2006 - Jul 2008).
3. **Ashley Stuckey, MD**. Inpatient, outpatient care and operating room techniques (Jul 2006 - Jun 30, 2007; Jan 2009 - Apr 2010).
4. **Katina Robison, MD**. Inpatient, outpatient care and operating room techniques (Jul 2007 - Jul 2008; Jan 2009 - Jun 2009).
5. **Shannon MacLaughlan, MD**. Inpatient, outpatient care and operating room techniques (Jul 2007 - Jul 2008; Jul 2009 - Apr 2010).
6. **Katrin Kristjansdottir, MD**. Inpatient, outpatient care and operating room techniques (Jan 2009 - Apr 2010).
7. **Nada Kwar, MD**. Inpatient, outpatient care and operating room techniques (Jul 2009 - Apr 2010).

SIU School of Medicine Minimally Invasive Surgery Fellow Teaching

1. **Arturo Garza, MD**. Inpatient, outpatient care and operating room techniques (Jul 2011 - Jun 2012).
2. **Tatnai L. Burnett, MD**. Inpatient, outpatient care and operating room techniques (Jul 2013 - Jun 2015).
3. **Jose Eugenio-Colon, MD**. Inpatient, outpatient care and operating room techniques (Jul 2015 – Jun 2017).

TEACHING IN RESEARCH SETTINGS

Brown University Undergraduate Student Research Mentoring

1. **Casey Leib**. BI/0195 S61 Independent Study. The Effect of Isothiocyanates on Solid Tumors (2005 - 2007, **Graduated May 2007**).
 - a. **Abstracts published/Posters presented** at the 38th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007.

- b. **Manuscript published in *Bioorg Med Chem Lett.* 2007;17(21):5846-5852.** Title: Effect of Indole Ethyl Isothiocyanates on Proliferation, Apoptosis and MAPK Signaling in Neuroblastoma Cell Lines.

Brown University Graduate Student Research Mentoring

1. **Tasha Hughes, MPH.** Co-Advisor on MPH thesis. The outcome of interest of this study is the deviation from the standard schedule of care, either between surgery and chemotherapy initiation or during the course of chemotherapy in women diagnosed with ovarian, fallopian tube or primary peritoneal cancer (2005 - 2006, **Graduated May 2006**).
 - a. **Abstract published/Poster presented** at the 37th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, Palm Springs, California, March 22-26, 2006.
 - b. **Manuscript published *Am J Clin Oncol.* 2008;31(1):39-42.** Title: For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?

SIU School of Medicine Obstetrics and Gynecology Medical Student Research Mentoring

1. **Kyley Maxheimer, MS-4.** Estrogen Metabolites as Biomarkers for Endometrial Cancer (Sep 2015 - present).
2. **Sofia Candel, MD (graduated May 2017).** Microbial Profiles and Tumor Markers from Culdocentesis: a Novel Screening Method for Epithelial Ovarian Cancer. **Abstract published/Poster presented** at the 2017 ACOG Annual Clinical and Scientific Meeting, San Diego, CA, May 6-9, 2017.
3. **Kacey Hamilton, MS-4.** Diagnostic Utility of Culdocentesis in Patients with a Suspicious Adnexal Mass and Endometrial Cancer and the Microbiome (2016 - present).

Brown University Obstetrics and Gynecology Resident Research Mentoring

1. **Carla Chibswewa, MD.** Exploring the Religious/Spiritual Needs of Gynecologic Cancer Patients and their Views on the Role their Physicians Should Take in Meeting Those Needs (2005 - 2006). **Abstract published/Poster presented** at the 36th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, Miami Beach, FL, March 19-23, 2005.
2. **Brenda Martin, MD.** Synchronous Ovarian Cancer in Young Women with Endometrial Cancer: A Retrospective Cohort Study (Jun 2006 - May 2008).

SIU School of Medicine Obstetrics and Gynecology Resident Research Mentoring

1. **Steven Radtke, MD.** Diagnostic Utility of Culdocentesis in Patients with a Suspicious Adnexal Mass. (Feb 2013 - Jun 2014).
2. **Anne Thomson, MD.** Diagnostic Utility of Culdocentesis in Patients with a Suspicious Adnexal Mass. (Jul 2014 – Jun 2016). **Abstract published/Poster presented** at the Simmons Cancer Institute at SIU, Basic and Translational Research Symposium. Springfield, IL, November 7, 2015. **Title:** Diagnostic Utility of Culdocentesis in Patients with a Suspicious Adnexal Mass.
3. **Kristen Kendall, MD.** Urinary Biomarkers for Endometrial Cancer. (Jul 2015 – present)
4. **Katelyn Pratt, MD.** Urinary Biomarkers for Endometrial Cancer. (Jul 2016 - present).
5. **Katherine Hyon, MD.** Rural-Urban Differences in Surgical Treatment and Regional Lymph Node Examination in Endometrial Cancer Patients. (Mar 2017 – present). **Abstract published/Poster presented** at the 2017 Rural Cancer Control: Challenges and Opportunities Meeting, Memphis, TN, May 4-5, 2017. **Title:** Rural-Urban Variation in Surgical Treatment, Lymph Node Examination, and Adequate Lymphadenectomy for Endometrial Cancer Patients.

Brown University Fellow Research Mentoring

1. **Carolyn McCourt, MD. Main project:** Iron Salophene is a Potent Inducer of Apoptosis in Ovarian Cancer (Nov 2005 - Jun 2006).

- a. **Abstract published/Poster presented** at the 26th Annual Meeting of the New England Association of Gynecologic Oncologists, Manchester, VT, June 9-11, 2006.
 - b. **Manuscripts published in *PLoS ONE***. **2008**;3(5):e2303. Title: Iron(III)-salophene: An organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. *Drug, Design, Development, and Therapy* **2009**;3:17-26. Title: Apoptotic and chemotherapeutic properties of Iron(III)-salophene in an ovarian cancer animal model.
2. **Katina Robison, MD. Main project:** Calcidiol and Ergocalciferol Derivatives for the Treatment of Ovarian Cancer in an Animal Model (Jul 2006 - Jun 2007).
 - a. **Abstract published/Poster presented** at the 27th Annual Meeting of the New England Association of Gynecologic Oncologists, Kennebunkport, ME, June 8-10, 2007. **First Prize Paper**. *Journal of Women's Health*, **2007**. Title: A Novel Non-Hypercalcemic Vitamin D Derivative in the Treatment of Ovarian Cancer. *Gynecologic Oncology*, **2008**. Title: The use of a vitamin D derivative in a mouse xenograft ovarian cancer model.
 - b. **Manuscripts published**. *Investigational New Drugs* **2010**;28(5):543-553. Title: Effect of a Vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. *Gynecol Oncol*. **2011**;123(2):370-378. Title: Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell cells. *PLoS One*. **2012**;7(4):e34443. Title: Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model.
 3. **Ashley Stuckey, MD. Main project:** Developing an Integrated Genomic Approach to Explore the Antitumor Activity of Vitamin D and Derivatives to Treat Ovarian Cancer (Jul 2007 - Jun 2008).
 - a. **Abstract published/Poster presented** at the 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, March 14-17, 2010.
 - b. **Manuscripts published** *Investigational New Drugs*, **2010**;28(5):543-553. Title: Effect of a Vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. *BMC Cancer*, **2011**;11:308. Title: Integrated Genomics of Ovarian Xenograft Tumor Progression and Chemotherapy Response.
 4. **Shannon MacLaughlan, MD. Main project:** Acquisition of human serous epithelial ovarian cancer specimens and serum for genomic analysis and development of novel cell lines (Jul 2008 - Jun 2009).
 - a. **Abstract published/Poster presented** at the 101st Annual AACR Meeting, Washington, DC, April 17-21, 2010. Title: Genetics of Primary and Metastatic Ovarian Cancer.
 - b. **Manuscripts published** *PLoS One*. **2013**;8(3):e58226. Title: Identification of ovarian cancer metastatic miRNAs. *Genes Cancer*. **2013**;4(11-12):524-534. Title: PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. *PLoS One*. **2014**;9(4):e94476. Title: Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease.
 5. **Katrin Kristjansdottir, MD. Main project:** Development of an Assay for the Early Detection of Ovarian Cancer. (Jul 2009 - Jun 2010).
 - a. **Abstract published/Poster presented** at 30th Meeting of the New England Association of Gynecologic Oncologists, Booth Bay, ME, Jun 11-13, 2010. Title: 7-Methyl Indole Ethyl Isothiocyanate- A Novel Cytotoxic Agent for Endometrial Cancer - **First Prize Paper**; and at the 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, March 6-9, 2011. **Abstract published** in *Gynecol Oncol*, **2011**;120(S1):S4.
 - b. **Manuscripts published** *Chemical Biology & Drug Design* **2010** Aug;76(2):164-173. Title: Chemotherapeutic Effect of Calcidiol Derivative B3CD in a Neuroblastoma Xenograft Model. 7-Methyl Indole Ethyl Isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells. *Gynecol Oncol*. **2012**;126(2):252-258.

SIU School of Medicine Fellow Research Mentoring

1. **Jose Eugenio-Colon, MD.** Dual Energy CT scan for the Evaluation of Pelvic Masses (Jan 2016 – Jun 2017)

GRANTS

Ongoing EXTERNAL Research Support

1. **P20CA192987** Brard (PI) 09/08/2015 - 08/31/2018
NIH/NCI \$1,306,000 (TC; \$652,994 SIUSM)
1/2 Addressing Rural Cancer Health Disparities: An SCC-SIUSM Partnership
The overall goal is to establish a highly integrated research and training collaboration focused on rural cancer health disparities between Southern Illinois University School of Medicine (SIUSM), an institution that serves the population of Downstate Illinois, a largely rural and socioeconomically disadvantaged region with significant cancer health disparities, and the Siteman Cancer Center at Washington University in St. Louis (SCC-WUSTL), an NCI-designated Cancer Center. The Partnership will build SIUSM's research capacity and success conducting NIH-funded cancer disparity research, while also enhancing SCC's rural cancer awareness, research and reach. By doing so, the Partnership will contribute to reducing the cancer health disparities that persist in rural populations.
Role: PI (SIUSM)

2. **ORNLLDRD8831** Brard (Co-PI subcontract) 10/1/2017-9/30/2019
DOE \$830,000 (TC; \$120,000 SIUSM)
A Quantitative, Systems Biology, Multi-omic Approach to Diagnose and Predict Response to Treatment for Gynecologic Cancers
The overall goal of this project is to leverage microbial ecological analysis to identify microbial signatures that can 1) detect a malignancy earlier in gynecologic cancer pathology, 2) provide preoperative staging of disease, and 3) indicate response to chemotherapy intervention
Role: Co-PI (SIUSM)

Ongoing INTERNAL Research Support

1. **Team Science Grant (TSG)** Braundmeier-Fleming A. (PI) 07/01/2017 - 06/30/2018
SIU School of Medicine \$100,000 (TC)
Machine Learning Approach for Early Detection and Individualized Treatment of Ovarian Cancer
The project goal is to utilize one's microbiome and a machine learning approach to develop a novel diagnostic tool for detecting ovarian cancer and predicting treatment responses through individualized comprehensive profiling.
Role: Co-I

2. **Team Science Grant (TSG)** Brard L./Hales B. (Co-PIs) 07/01/2014 - 06/30/2016
SIU School of Medicine \$100,000 (TC) NCE 07/01/2016 – 06/30/2018
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
The project goals are to determine the feasibility of administering a daily 20g dose of ground flaxseed to ovarian cancer patients in clinical remission and describe the PFS in ovarian cancer patients in clinical remission following adjuvant chemotherapy and flaxseed supplementation.
Role: Co-PI

Past EXTERNAL Research Support

1. **R03CA181907** Brard (PI) 12/01/2013 - 11/30/2015
NIH/NCI \$147,500 (TC) NCE 12/01/2015 - 11/30/2016
Diagnostic Utility of Culdocentesis in Patients with a Suspicious Adnexal Mass
The project goal is to determine if tumor markers (CA125 and HE4) from cul-de-sac washings and subsequent cytology correlate with ovarian cancer diagnosis in patients with an adnexal mass suspicious for malignancy.
Role: PI

2. **L30 CA170963** Brard (PI) 07/01/2012 - 06/30/2014
NIH/NCI \$70,000 (TC)
Treatment and Biomarker Discoveries for Ovarian Cancer
Role: PI

3. **R01CA136491*** Brard L (PI) 06/01/2009 - 06/30/2010
 NCI/NIH \$2,100,000 (TC) was 06/01/2009 - 04/30/2014*
Development of an Assay for the Early Detection of Ovarian Cancer.
 Ovarian cancer is one of the most lethal cancers affecting women. This is due to the inability to detect it while still localized to the ovaries. Early detection would result in a 90% survival rate. LPA, a currently controversial biomarker for ovarian cancer diagnosis, is the subject of this application. A simple new method for detecting LPA and a fresh approach to validating LPA's reliability as an accurate biomarker would emanate from the proposed studies.
Role: PI
***Previous institution declined to transfer this grant to current institution.**
4. **R01EB002044** Strongin R (PI) 07/31/2007 - 06/30/2010
 NIBIB \$720,000 (TDC)
Synthesis and Study of Novel Sensing Agents.
 The major goals of this project were to contribute to (i) clarifying the current understanding of the role of homocysteine in disease and (ii) facilitate the study homocysteine in natural media.
Role: Collaborator
5. **P41RR001395** - Supplemental Smith P (PI) 10/01/2009 - 06/30/2010
 NIH/NCRR
BioCurrents Research Center - Mechanisms of Cisplatin Resistance in Ovarian Cancer
 The major goals of this project were to understand the genetic and phenotypic differences between primary and metastatic ovarian cancer growths that may affect therapeutic response. We expected to genotype each tumor and match the genetic differences to drug response phenotypes including probing cisplatin sensitivity relative to the regulation of drug efflux systems.
Role: Significant Contributor
6. **R21NS051408** Brard L (PI) 12/01/2007 - 11/30/2009
 NIH/NINDS \$335,190 (TC)
High-Risk Neuroblastoma: A Devastating Childhood Cancer.
 The major goals of this project were to develop new therapeutic agents for neuroblastoma.
Role: PI
7. **K12HD043447** Coustan DR (PI) 01/01/2006 - 07/31/2008
 BIRCWH \$100,000 (TDC)
3-Bromoacetoxy-Calcidiol as a Novel agent in Ovarian Cancer Therapy.
 BIRCWH (Building Interdisciplinary Research Careers in Women's Health) Scholars is a NIH funded institutional K12 mechanism that protects 75% of the time for young MD and/or PhD researchers so as to help launch their careers toward independent funding. The major goal of this BIRCWH project was to test 3-bromoacetoxy-calcidiol in ovarian cancer cell lines and an animal model.
Role: Scholar
8. **Ovarian Cancer Research Fund, Inc.** Brard L (PI) 01/01/2006 - 12/31/2007
 Individual Investigator Grant (Awarded) \$100,000 (TC)
Liposomal Iron Chelator Derivatives in Ovarian Cancer Therapy.
 The major goals of this project were the synthesis, development and testing of novel liposomal iron chelators and derivatives in ovarian cancer cell lines.
Role: PI
9. **APGO/Organon Med Ed Research Award** Brard L (PI) 07/01/2003 - 06/30/2004
 APGO/Organon \$15,000 (TC)
End of Life and Complementing Care: Development and Integration of a Longitudinal Resident Teaching Curriculum into a Gynecologic Oncology Rotation.
 The major goal of this project was to develop a resident curriculum to expand knowledge in the field of palliative care pertaining to gynecologic oncology patients.
Role: PI

Past INTERNAL Research Support

1. **Patient-Oriented Research Grant (PORG)** Brard L./Hales B. (Co-PIs) 01/01/2014-03/30/2015
SIU School of Medicine \$25,000 (TC)
Assessment of Estrogen Metabolite Ratios as a Predictive Biomarker for Ovarian Cancer
The project goal was to determine if the ratio of the estrogen metabolites, 2-OHE₁/16 α -OHE₁, in urine correlates with a diagnosis of epithelial ovarian cancer.
Role: Co-PI

2. **Team Science Grant (TSG)** Campbell K. (PI) 07/01/2013-06/30/2015
Simmons Cancer Institute/SIU School of Medicine \$100,000 (TC)
Objective Electrophysiological Analysis of "Chemobrain" through the Auditory System
The project goal was to determine if a non-invasive, time-efficient auditory electrophysiological method can detect chemobrain.
Role: Collaborator

3. **EAM-Award** Hayashi K (PI) 04/01/2012-03/30/2013
SIU-School of Medicine \$50,000 (TC)
Does Niclosamide inhibit ovarian tumor growth and progression regulated by WNT7A in a pre-clinical model?
The major goal of this project was to determine the potential of Niclosamide to inhibit ovarian cancer *in vitro* and *in vivo*. This data will then be used to apply for NIH funding.
Role: Co-Investigator

4. **EAM-Near Miss Award** Brard L (PI) 04/01/2011-09/30/2012
SIU-School of Medicine \$12,500 (TC)
A Phase I Trial of Bithionol for Recurrent Epithelial Ovarian Cancer.
The major goal of this project was to perform a pilot efficacy trial of Bithionol in an animal model of ovarian cancer. This data will then be used to apply for NIH or FDA funding for a human Phase 1 trial.
Role: PI

5. **National Center of Excellence in Women's Health** Brodsky A (PI) 11/01/2008-04/01/2010
Innovations in Women's Health Research Seed Grant \$20,000 (TC)
(Brown University / Women & Infants Hospital)
Exploring cisplatin sensitivity of primary and metastatic ovarian tumors
The aim of this seed grant was to understand the genetic differences between primary and metastatic ovarian cancer growths that may affect therapeutic response using comparative genomic hybridization (CGH) and mRNA expression profiling.
Role: Co-PI

6. **Seed Grant Brown University** Brodsky A (PI) 03/01/2007-02/28/2008
Office of the Vice President for Research \$90,000 (TC)
Developing an Integrated Genomic Approach to Explore the Antitumor Activity of Vitamin D and Derivatives to Treat Ovarian Cancer.
The aim of this seed grant was to take a global genomic view to understand the effect of vitamin D (calcitriol) and the vitamin D derivative, MT19C, on ovarian tumors.
Role: Co-PI

7. **Seed Grant Brown University** Brard L (PI) 02/01/2005-06/30/2007
Office of the VP for Research \$75,000 (TC)
Development and Optimization of Novel Chemotherapeutic Agents for Cancer.
The major goals of this project were the synthesis, development and testing of novel chemotherapeutic agents based on the vitamin D lead compound developed in the laboratory.
Role: PI

8. **Seed Grant** Brard L (PI) 05/01/2003 - 04/31/2006
Department of Obstetrics and Gynecology \$10,000 (TC)
Evaluation of Iron Chelators in Tandem with Vitamin D Analogs in the Treatment of Ovarian Cancer in an Animal Model.
The major goal of this project was to test a combination of two novel classes of chemotherapeutic agents in an ovarian cancer animal model.
Role: PI

9. **Division Grant** Brard L (PI) 07/01/2002 - 06/30/2003
 Program in Women's Oncology (WIHRI) \$15,000 (TC)
The Use of Iron Chelators in the Treatment of Gynecologic Malignancies.
 The major goals of this project were to develop iron chelators as novel chemotherapeutic agents in gynecologic malignancies.
Role: PI

INDUSTRIAL FUNDING

1. AMGEN inc. AMG 386 20060342 Contract value = \$357,360 02/25/2008 - 04/30/2010
A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination with AMG 386 in Subjects with Advanced Recurrent Epithelial Ovarian or Primary Cancer.
Role: Site Co-PI at Women & Infants Hospital

PUBLICATIONS (*corresponding/senior author) (Peer-Reviewed)

1. Praly JP, Brard L, Descotes G. Spiroorthoester de Sucres C1 gem-Dihalogénés. *Tetrahedron Lett.* 29:2651-2654 (1988).
2. Praly JP, Brard L, Descotes G. Photohalogenations of Halogenated Glycopyrannosyles: A New Route to C1 gem-Dihalogenated Sugars. *Tetrahedron.* 45:4141-4152 (1989).
3. Praly JP, El Kharraf Z, Corringer PJ, Brard L, Descotes G. Orthoesterification de Sucres C1 gem-Dihalogénés. *Tetrahedron.* 46:65-75 (1990).
4. Conticello VP, Brard L, Giardello MA, Tsuji Y, Sabat M, Stern C, Marks TJ. Chiral Organolanthanide Complexes for Enantioselective Olefin Hydrogenation. *J Am Chem Soc.* 114:2761-2762 (1992).
5. Gagné MR, Brard L, Conticello VP, Giardello MA, Stern C, Marks TJ. Stereoselection Effects in the Catalytic Hydroamination/Cyclization of Amino Olefins at Chiral Organolanthanide Centers. *Organometallics.* 11:2003-2007 (1992).
6. Fischer JE, Luzzi DE, Kniaz K, McGhie AR, Ricketts-Foot DA, Romanow WJ, Vaughan GBM, Heiney PA, Li D, Smith AL, Strongin RM, Cichy MA, Brard L, Smith III AB. On the Existence of Higher-Order Superlattices in Orientationally-Ordered C₆₀. *Phys Rev.* B47:14614-14617 (1993).
7. Kiefl RF, MacFarlane A, Chow K, Dunsiger S, Duty TL, Johnston TMS, Schneider JW, Sonier J, Brard L, Strongin RM, Fischer JE, Smith III AB. Coherence Peak and Superconducting Energy Gap in Rb₃C₆₀ Observed by Muon Spin Relaxation. *Phys Rev Lett.* 70:3987-3990 (1993).
8. Smith III AB, Strongin RM, Brard L, Furst GT, Romanow WJ, Owens KG, King RC. 1,2-Methanobuckminsterfullerene C₆₁H₂, the Parent Fullerene Cyclopropane: Synthesis and Structure. *J Am Chem Soc.* 115:5829-5830 (1993).
9. Yildirim T, Fischer JE, Harris AB, Stephens PW, Liu D, Brard L, Strongin RM, Smith III AB. Orientational Phase Transition in Na_xC₆₀ (1 < x < 3). *Phys Rev Lett.* 71:1383-1386 (1993).
10. Giardello MA, Conticello VP, Brard L, Sabat M, Rheingold A, Stern C, Marks TJ. Chiral Organolanthanides Designed for Asymmetric Catalysis. Synthesis, Characterization, and Configurational Interconversions of Chiral, C₁-Symmetric Organolanthanide Halides, Amides, and Hydrocarbyls. *J Am Chem Soc.* 116:10212-10240 (1994).
11. Giardello MA, Conticello VP, Brard L, Gagné MR, Marks TJ. Chiral Organolanthanides Designed for Asymmetric Catalysis. A Kinetic and Mechanistic Study of Enantioselective Olefin Hydroamination/Cyclization and Hydrogenation by C₁-Symmetric Me₂Si(Me₄C₅)(C₅H₃R*)Ln Complexes where R* = Chiral Auxiliary. *J Am Chem Soc.* 116:10241-10254 (1994).

12. Lommen AN, Heiney PA, Vaughan GBM, Stephens PW, Liu D, Li D, Smith AL, McGhie AR, Strongin RM, Brard L, Smith III AB. Structure and Phase Transition of the Annulene (6:5) Isomer of C₆₁H₂. *Phys Rev B*. 49:12572-12567 (1994).
13. MacFarlane WA, Kiefl RF, Chow K, Dunsiger S, Duty TL, Johnston TMS, Schneider JW, Sonier S, Brard L, Strongin RM, Fischer JE, Smith III AB. Hebel-Slichter Peak and Superconducting Energy Gap in Rb₃C₆₀ Observed by Muon Spin Relaxation. *Hyperfine Interact.* 86:467 (1994).
14. Duty TL, Brewer JH, Chow K, Kiefl RF, Macfarlane AW, Morris GD, Schneider JW, Hitti B, Lichti R, Brard L, Fischer JE, Smith III AB, Strongin RM. Zero-Field μ SR in Crystalline C₆₀. *Hyperfine Interact.* 86:789-795 (1994).
15. Smith III AB, Strongin RM, Brard L, Furst GT, Romanow WJ, Owens KG, Goldschmidt RJ. C₇₁H₂ Cyclopropanes and Annulenes: Synthesis and Characterization. *J Chem Soc, Chem Commun.* 2187-2188 (1994).
16. Cardini G, Bini R, Salvi PR, Schettino V, Klein ML, Strongin RM, Brard L, Smith III AB. The Infrared Spectrum of Two Fullerene Derivatives: C₆₀O and C₆₁H₂. *J Phys Chem.* 96:9966-9971 (1994).
17. Smith III AB, Strongin RM, Brard L, Romanow WJ, Saunders M, Jiménez-Vázquez HA, Cross RJ. Synthesis and ³He NMR Studies of C₆₀ and C₇₀ Epoxide, Cyclopropane and Annulene Derivatives Containing Endohedral Helium. *J Am Chem Soc.* 116:10831-10832 (1994).
18. Giardello MA, Yamamoto Y, Brard L, Marks TJ. Stereocontrol in the Polymerization of Methyl Methacrylate Mediated by Chiral Organolanthanide Metallocenes. *J Am Chem Soc.* 117:3276-3277 (1995).
19. Bortchagovsky EG, Yurchenko IA, Romanow WJ, Brard L. Optical Properties of Fullerene C₆₀ Film in the Vicinity of Orientational Phase Transition Probed by Ellipsometry. *J Molec Struct.* 349:187-190 (1995).
20. Smith III AB, Strongin RM, Brard L, Furst GT, Romanow WJ, Owens KG, Goldschmidt RJ, King RC. Synthesis of Prototypical Fullerene Cyclopropanes and Annulenes; Isomer Differentiation via NMR and UV Spectroscopy. *J Am Chem Soc.* 117:5492-5502 (1995).
21. Dinnebier RE, Stephens PW, Carter JK, Lommen AN, Heiney PA, McGhie AR, Brard L, Smith III AB. X-ray Powder Diffraction Structure of Triclinic C₆₀Br₂₄(Br₂)₂. *J Appl Cryst.* 28:327-334 (1995).
22. Fu PF, Brard L, Li Y, Marks TJ. Regioselection and Enantioselection in Organolanthanide-Catalyzed Olefin Hydrosilylation. A Kinetic and Mechanistic Study. *J Am Chem Soc.* 117:7157-7168 (1995).
23. Yurchenko I, Burstein E, Kazantseva Z, Romanow WJ, Brard L. The Dependence of the Symmetry (Spin) Forbidden Photoluminescence of C₆₀ Molecules on their Proximity to Metal. *Ultramicroscopy.* 61:259-263 (1995).
24. Smith III AB, Strongin RM, Brard L, Furst GT, Atkins JH, Romanow WJ, Saunders M, Jiménez-Vázquez HA, Owens KG, Goldschmidt RJ. Synthesis and Characterization of the First C₇₀ Epoxides. Utilization of ³He NMR in Analysis of Fullerene Derivatives. *J Org Chem.* 61:1904-1905 (1996).
25. Meingast C, Roth G, Pintschovius L, Michel RH, Stoermer C, Kappes MM, Heiney PA, Brard L, Strongin RM, Smith III AB. Structure, Dynamics, and Phase Transitions in the Fullerene Derivatives C₆₀O and C₆₁H₂. *Phys Rev B Cond Mat.* 54:124-131 (1996).
26. Lundin A, Soldatov A, Sundqvist B, Strongin RM, Brard L, Fischer JE, Smith III AB. Compressibility of C₆₁D₂ up to One GPa in the Temperature Range 175-345 K. *Carbon.* 34:1119-1121 (1996).
27. Kalkunte S, Brard L*, Granai CO, Swamy N. Inhibition of Angiogenesis by Vitamin D-binding Protein: Characterization of Antiendothelial Activity of DBP-maf. *Angiogenesis.* 8:349-360 (2005). PMID: 16400520.
28. Brard L*, Granai CO, Swamy N. Iron Chelators Deferoxamine and Diethylenetriamine Pentaacetic Acid Induce Apoptosis in Ovarian Carcinoma. *Gynecol Oncol.* 100:116-127 (2006). PMID: 16203029.

29. Robison K, Steinhoff MM, Granai CO, Brard L, Gajewski W, Moore RG. Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes. *Gynecol Oncol*. 101:24-27 (2006). PMID: 16246399.
30. Kalkunte S, Swamy N, Dizon DS, Granai CO, Brard L*. Benzyl Isothiocyanate (BITC) Induces Apoptosis in Ovarian Carcinoma. *Journal of Experimental Therapeutics and Oncology*, 5(4):287-300 (2006). PMID: 17024969.
31. Brard L*, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, Moore RG, Granai CO. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. *Gynecol Oncol*. 103:176-180 (2006). PMID: 16564074.
32. Satyan KS, Swamy N, Dizon DS, Singh R, Granai CO, Brard L*. Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation. *Gynecol Oncol*. 103:261-270 (2006). PMID: 16624391.
33. Robison K, Steinhoff MM, Granai CO, Brard L, Gajewski W, Moore RG. Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes. *Obstetrical & Gynecological Survey*. 61(8):518-519 (2006). doi: 10.1097/01.ogx.0000228679.73248.c9.
34. Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, Dizon DS. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants Hospital. *Gynecol Oncol*. 105(1):81-83 (2007). PMID: 17157366.
35. Singh RK, Lange TS, Kim K, Zou Y, Lieb C, Sholler GL, Brard L*. Effect of Indole Ethyl Isothiocyanates on Proliferation, Apoptosis and MAPK Signaling in Neuroblastoma Cell Lines. *Bioorg Med Chem Lett*. 17(21):5846-5852 (2007). PMID: 17855093.
36. Lange TS, Singh RK, Kim K, Zou Y, Kalkunte S, Sholler GL, Swamy N, Brard L*. Anti-proliferative and Pro-apoptotic Properties of 3-Bromoacetoxy Calcidiol (B3CD) in High-Risk Neuroblastoma. *Chem Biol Drug Des*. 70(4):302-310 (2007). PMID: 17937776.
37. Dizon DS, McCourt CK, Martin-Hanley T, Brard L, Bradley AM, Bandera C. Adjuvant therapy for endometrial cancer: "sandwich therapy" of carboplatin and paclitaxel with radiation therapy. The Women & Infants Hospital experience and review of the literature. *Cancer Therapy*. 5: 395-400 (2007).
38. Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, DiSilvestro P. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? *Am J Clin Oncol*. 31(1):39-42 (2008). doi: 10.1097/COC.0b013e318134ee6f. PMID: 18376226
39. Singh RK, Lange TS, Kim K, Singh AP, Hopson R, Vorsa N, Brard L*. Synthesis of Bicyclic Aryl Thiazolines with Selective Anti-Proliferative Effects on Human Cancer Cell Lines. *Letters in Organic Chemistry*. 5(2):103-109 (2008). doi: 10.2174/157017808783743966.
40. Moore RG, Robison K, Brown AK, Disilvestro P, Steinhoff M, Noto R, Brard L, Granai CO. Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: A prospective trial. *Gynecol Oncol*. 109(1):65-70 (2008). doi: 10.1016/j.ygyno.2007.12.027. PMID: 18255128.
41. Singh RK, Lange TS, Kim K, Shaw S, Brard L*. A Novel Indole Ethyl Isothiocyanate (7Me-IEITC) with Anti-proliferative and Pro-apoptotic Effects on Platinum-resistant Human Ovarian Cancer Cells. *Gynecol Oncol*. 109(2):240-249 (2008). doi: 10.1016/j.ygyno.2008.01.042. PMID: 18329084.
42. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L*. Iron(III)-salophene: An organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. *PLoS ONE*. 3(5):e2303 (2008). doi: 10.1371/annotation/d97d24fc-aa07-40fd-88b2-6b2e050ddb31. PMID: 18509533.

43. Singh RK, Lange TS, Kim KK, Singh AP, Vorsa N, Brard L*. Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signaling and cell cycle regression in ovarian cancer cells. *Br J Cancer*. 99(11):1823-1831 (2008). doi: 10.1038/sj.bjc.6604778. PMID: 19002174.
44. Brard L*, Singh RK, Kim KK, Lange TS, Saulnier Sholler GL. Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-Butyl Carbamoyl, 7-Methyl-Indole-3-Ethyl Isothiocyanate (NB7M) in nervous system cancer cells. *Drug Design, Development and Therapy*. 2:61-69 (2009). PMID: 19920894.
45. Lange TS, McCourt C, Singh RK, Kim KK, Singh AP, Luisi BS, Alpturk O, Strongin R, Brard L*. Apoptotic and chemotherapeutic properties of Iron(III)-salophene in an ovarian cancer animal model. *Drug Design, Development and Therapy*. 3:17-26 (2009). PMID: 19920918.
46. Singh AP, Singh RK, Kim KK, Kalkunte SS, Nussbaum R, Kim KK, Torres M, Brard L*, Vorsa N. Cranberry Proanthocyanidins are Cytotoxic to Human Cancer Cells and Sensitize Platinum-Resistant Ovarian Cancer Cells to Paraplatin. *Phytother Res*. 23(8):1066-1074 (2009). PMID: 19172579.
47. Saulnier Sholler GL, Brard L, Straub JA, Dorf L, Illyene S, Kalkunte S, Bosenberg M, Ashikaga N, Nishi R. Nifurtimox Induces Apoptosis of Neuroblastoma Cells in Vitro and in Vivo. *J Pediatr Hematol Oncol*. 31(3):187-193 (2009). doi: 10.1097/MPH.0b013e3181984d91. PMID: 19262245.
48. McCourt C, Dessie S, Bradley AM, Schwartz J, Brard L, Dizon DS. Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer? *Int J Gynecol Cancer*. 19(3): 343-347 (2009). doi: 10.1111/IGC.0b013e3181a12eb9. PMID: 19407557.
49. Lange TS, Stuckey AR, Robison K, Kim KK, Singh RK, Raker CA, Brard L*. Effect of a Vitamin D3 derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. *Invest New Drugs*. 28(5): 543-53 (2010). PMID: 19582372. doi: 10.1007/s10637-009-9284-y. PMID: 1958237.
50. Kim K, Lange TS, Singh R, Brard L*. Lipophilic aroylhydrazone chelator HNTMB and its multiple effects in ovarian cancer cells. *BMC Cancer*. 10:72 (2010). PMID: 20184758. doi: 10.1186/1471-2407-10-72. PMID: 20184758.
51. Lange TS, Zou Y, Singh R, Kim K, Kristjansdottir K, Saulnier-Sholler GL, Brard L*. Chemotherapeutic Effect of Calcidiol Derivative B3CD in a Neuroblastoma Xenograft Model. *Chem Biol Drug Des*. 76(2):164-73 (2010). PMID: 20492445. doi: 10.1111/j.1747-0285.2010.00988.x. PMID: 20492445.
52. Singh R, Lange TS, Kim KK, Brard L*. A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells. *Invest New Drugs*. 29(1):63-72 (2011). PMID: 19865799. doi: 10.1007/s10637-009-9335-4. PMID: 19865799.

PAPERS PUBLISHED WHILE AT SIU

53. Saulnier Sholler G, Bergendahl G, Brard L, Singh AP, Heath B, Bingham P, Ashikaga T, Kamen B, Homans A, Ferguson W. A Phase I Study of Nifurtimox in Patients with Relapsed/Refractory Neuroblastoma. *J Pediatr Hematol Oncol*. 33(1):25-30 (2011). doi: 10.1097/MPH.0b013e3181f47061. PMID: 21063221.
54. Koto KS, Lescault P, Brard L, Kim KK, Singh RK, Bond J, Illyene S, Slavik MA, Ashikaga T, Saulnier Sholler GL. Antitumor and Genomic Activity of Nifurtimox is Enhanced with Tetrathiomolybdate in Medulloblastoma *in vitro*. *Int J Oncol*. 38(5):1329-1341 (2011). doi: 10.3892/ijo.2011.971. PMID: 21399873.
55. Kim KK, Singh RK, Strongin RM, Moore RG, Brard L, Lange TS. Organometallic Iron(III)-Salophene Exerts Cytotoxic Properties in Neuroblastoma Cells via MAPK Activation and ROS Generation. *PLoS ONE* 6(4):e19049 (2011). doi:10.1371/journal.pone.0019049. PMID: 21559503.
56. Singh R, Dorf L, DeMartino A, Illyene S, Koto K, Ashikaga T, Kim KK, Brard L, Saulnier Sholler GL. Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in Vitro. *Cancer Biol Ther*. 11(12):1036-1045 (2011). PMID: 21532338.
57. Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG. Tetrathiomolybdate Induces Doxorubicin Sensitivity in Resistant Endometrial Tumor Cell Lines. *Gynecol Oncol*. 122(1):183-189 (2011). doi: 10.1016/j.ygyno.2011.03.035. PMID: 21529906.

58. Miller DH, Fischer A, Chu K, Burr R, Hillenmeyer S, [Brard L](#), Brodsky AS. T090137 Inhibits Cisplatin Induced Apoptosis in Ovarian Cancer Cells. *Int J Gynecol Cancer*. 21(8):1350-1356, (2011). doi: 10.1097/IGC.0b013e318228f558. PMID: 21921802.
59. Stuckey AR, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, [Brard L](#), Brodsky AS. Integrated Genomics of Ovarian Xenograft Tumor Progression and Chemotherapy Response. *BMC Cancer*. 11:308, (2011). doi: 10.1186/1471-2407-11-308. PMID: 21781307.
60. Fischer A, Kristjansdottir K, Miller DH, MacLaughlan S, Lapuk A, Collins C, Steinhoff M, [Brard L](#), Brodsky AS. Integrated genomics reveals metastatic drivers of ovarian cancer. *Clinical & Experimental Metastasis* 28(2):210-211 (2011). doi: 10.1007/s10585-010-9361-9.
61. [Brard L](#), Lange TS, Robinson K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK. Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cells. *Gynecol Oncol*. 123(2):370-8 (2011). doi: 10.1016/j.ygyno.2011.07.002. PMID: 21803404.
62. Lange TS, Horan T, Kim KK, Singh AP, [Brard L](#), Moore RG, Singh RK. Cytotoxic properties of Adamantyl-isothiocyanate and potential in vivo metabolite Adamantyl-N-acetylcystein in gynecological cancer cells. *Chem Biol Drug Des*. 79(1):92-103 (2012). doi: 10.1111/j.1747-0285.2011.01251.x. PMID: 21974809.
63. Singh AP, Lange TS, Kim KK, [Brard L](#), Horan T, Moore RG, Vorsa N, Singh RK. Purified cranberry proanthocyanidins (PAC-1A) cause proapoptotic signaling, ROS generation, Cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells. *Int J Oncol*. 40(1):99-108 (2012). doi:10.3892/ijo.2011.1225. PMID: 21994123.
64. Kim KK, Singh AP, Singh RK, DeMartino A, [Brard L](#), Vorsa N, Lange TS, Moore RG. Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. *Int J Oncol*. 40(1):227-235 (2012). doi:10.3892/ijo.2011.1198. PMID: 21922132.
65. Yoshioka S, King ML, Ran S, Okuda H, MacLean II JA, McAsey ME, Sugino N, [Brard L](#), Watabe K, Hayashi K. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/ β -catenin pathway. *Mol Cancer Res*. 10(3):469-482 (2012). doi:10.1158/1541-7786.MCR-11-0177. PMID: 22232518. **This paper was one of the most highly-cited (top five) Molecular Cancer Research articles published in 2012.**
66. Kim KK, Lange TS, Singh RK, [Brard L](#), Moore RG. Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C. *BMC Cancer*. 12(1):147 (2012). doi: 10.1186/1471-2407-12-147. PMID: 22502731.
67. Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, [Brard L](#), Depaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK. Efficacy of a Non-Hypercalcemic Vitamin D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model. *PLoS One*. 7(4):e34443 (2012). doi:10.1371/journal.pone.0034443. PMID: 22509304.
68. Kristjansdottir K, Kim K, Choi JS, Horan TC, [Brard L](#), Moore RG, Singh RK. 7-Methyl Indole Ethyl Isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells. *Gynecol Oncol*. 126(2):252-258 (2012). doi:10.1016/j.ygyno.2012.04.041. PMID: 22561404.
69. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, [Brard L](#), Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. *Gynecol Oncol*. 127(1):141-146 (2012). doi:10.1016/j.ygyno.2012.06.028. PMID: 22750258.
70. Vang S, Wu HT, Fischer A, Miller DH, Maclaughlan S, Douglass E, Steinhoff M, Collins C, Smith PJ, [Brard L](#), Brodsky AS. Identification of Ovarian Cancer Metastatic miRNAs. *PLoS One*. 8(3):e58226 (2013). doi:10.1371/journal.pone.0058226. PMID: 23554878.
71. Kawar N, Maclaughlan S, Horan TC, Uzun A, Lange TS, Kim KK, Hopson R, Singh AP, Sidhu PS, Glass KL, Shaw S, Padbury JF, Vorsa N, Arnold LA, Moore RG, [Brard L](#), Singh RK. PT19c, Another Non-hypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. *Genes Cancer*. 4(11-12):524-534 (2013). doi: 10.1177/1947601913507575. PMID: 24386512.

72. Ayyagari V, Brard L*. Bithionol Inhibits Ovarian Cancer Cell Growth In Vitro - Studies on Mechanism(s) of Action. *BMC Cancer*. 14(1):61-77 (2014). doi: 10.1186/1471-2407-14-61. PMID: 24495391.
73. Brodsky AS, Fischer A, Miller DH, Vang S, MacLaughlan S, Wu H-T, Yu J, Steinhoff M, Collins C, Smith PJS, Raphael BJ, Brard L. Expression Profiling of Primary and Metastatic Ovarian Tumors Reveals Differences Indicative of Aggressive Disease. *PLoS One*. 9(4):e94476 (2014). doi:10.1371/journal.pone.0094476. PMID: 24732363.
74. Ayyagari VN, Johnston NA, Brard L*. Assessment of the anti-tumor potential of Bithionol in vivo using a xenograft model of ovarian cancer. *Anticancer Drugs*. 27(6):547-559 (2016). doi: 10.1097/CAD.0000000000000364. PMID: 27058706.
75. Ayyagari VN, Hsieh TJ, Diaz-Sylvester PL, Brard L*. Evaluation of the Cytotoxicity of the Bithionol - Cisplatin Combination in a Panel of Human Ovarian Cancer Cell Lines. *BMC Cancer*. 17(1):49-64 (2017). doi: 10.1186/s12885-016-3034-2. PMID: 28086831
76. Alanee S, Delfino K, Robinson K, Brard L, Semaan A. Single Nucleotide Variant in Nucleoporin 107 may be Predictive of Sensitivity to Chemotherapy in Patient with Ovarian Cancer. *Pharmacogenet Genomics*. 27(7):264-269 (2017). doi: 10.1097/FPC.0000000000000288. PMID: 28562428
77. Zahnd WE, James AS, Jenkins WD, Izadi SR, Fogleman AJ, Steward DE, Colditz GA, Brard L*. Rural-Urban Differences in Cancer Incidence and Trends in the United States. *Cancer Epidemiol Biomarkers Prev*. 2017 Jul 27. pii: cebp.0430.2017. doi: 10.1158/1055-9965.EPI-17-0430. [Epub ahead of print]. PMID: 28751476.
78. Ayyagari VN, Diaz-Sylvester PL, Hsieh TJ, Brard L*. Evaluation of cytotoxicity of the Bithionol and Paclitaxel combination treatment in a panel of human ovarian carcinoma cell lines. *PLoS One*. 12(9):e0185111 (2017). doi: 10.1371/journal.pone.0185111. eCollection 2017. PMID: 28931042
79. Zahnd WE, Hyon KS, Diaz-Sylvester P, Izadi SR, Colditz GA, Brard L*. Rural-Urban Differences in Surgical Treatment and Regional Lymph Node Examination in Endometrial Cancer Patients. *Cancer Causes & Control*. 2017 Dec 27. doi: 10.1007/s10552-017-0998-4. [Epub ahead of print]. PMID: 29282582.
80. Zahnd WE, Jenkins WD, James AS, Izadi SR, Steward DE, Fogleman AJ, Colditz GA, Brard L*. Utility and Generalizability of Multi-State, Population-Based Cancer Registry Data for Rural Cancer Surveillance Research in the United States. *Cancer Epidemiol Biomarkers Prev*. 2018. Accepted for publication.

PATENTS

- Marks TJ, Yamamoto Y, Brard L, Giardello M. Method for Catalytic Polymerization of Substituted Acrylates. US Patent 5,312,881 (granted May 17, 1994).
- Brard L, Kalkunte S, Singh R. Heterocycles and Derivatives Thereof and Methods of Manufacture and Therapeutic Use. PCT/US 2006/047320. **Published June 21, 2007.**
- Brard L, Kalkunte S, Singh R, Strongin R, Alpturk O. Organometallic Compounds as Therapeutic Agents. WO/2008/070557, PCT/US2007/086080. **Published June 12, 2008.**
- Brard L, Singh RK, Kim K, Sholler G. N-Amino Tetrahydrothiazine Derivatives, Method of Manufacture and Use. WO/2008/091946, PCT/US2008/051794. **Published July 31, 2008.**
- Sholler G, Sundaresha HM, Kalkunte S, Singh RK, Brard L, Kim K. Nitrofurans Compounds for The Treatment of Cancer and Angiogenesis. PCT/US 2007/001527. **Published September 27, 2008. Licensed to Metronom-X Inc. Underwent a phase-IIb clinical trial for treatment of high risk pediatric neuroblastoma and medulloblastoma.**
- Wu HT, Brard L, Brodsky AS. MicroRNAs as Diagnostic Biomarkers and Therapeutics for Ovarian Cancer and Metastatic Tumors that Disseminate within the Peritoneal Cavity. PCT/US2012/033. **Filed April 15, 2012.**
- Singh AP, Kalkunte S, Singh RK, Vorsa N, Brard L, Schaich KM, Kim K. Compositions of "FAO-Free" Cranberry extracts, their complexes and Biological applications. (2006 March): US Patent applied.

ABSTRACTS (Including International Meetings)

1. Brard L. Synthesis, Structure, Reactivity, Kinetics, and Mechanisms of New Organolanthanide Complexes Involved in Catalytic Asymmetric Olefin Transformations. *Diss. Abstr. Int. B*, 53, 2865-2866 (1992).
2. Conticello VP, Brard L, Giardello MA, Tsuji Y, Sabat M, Marks TJ. Homogeneous Enantioselective Hydrogenation with Chiral Organolanthanide Complexes, 197th ACS National Meeting of the American Chemical Society, Dallas, TX, April 9-14, paper INOR 31 (1989).
3. Marks TJ, Conticello VP, Brard L, Giardello MA, Tsuji Y, Sabat M. Enantioselective Homogeneous Catalysis with Chiral Organolanthanide Complexes. 199th ACS National Meeting of the American Chemical Society, Boston, MA, April 22-27, paper INOR 551 (1990).
4. Gagné MR, Brard L, Conticello VP, Giardello MA, Marks TJ. Organolanthanide Catalyzed Hydroamination, Regio-, Diastereo- and Enantioselectivity Effects in the Cyclization of Amino-Olefins. 199th ACS National Meeting of the American Chemical Society, Boston, MA, April 22-27, CATL 14 (1990).
5. Giardello MA, Conticello VP, Gagné MR, Brard L, Rheingold AL, Stern CL, Marks TJ. Catalytic Asymmetric Hydrogenation and Hydroamination by Chiral Organolanthanide Complexes. 203rd ACS National Meeting of the American Chemical Society, San Francisco, CA, April 5-10, INOR 320 (1992).
6. Yamamoto Y, Giardello MA, Brard L, Marks TJ. Stereoregular Polymerization of Methyl Methacrylate by Chiral Organolanthanide Complexes. 205th ACS National Meeting of the American Chemical Society, Denver, CO, March 28-April 2, INOR 68 (1993).
7. Yamamoto Y, Giardello MA, Brard L, Marks TJ. Stereoregular Polymerization of Methyl Methacrylate by Chiral Organolanthanide Complexes. 206th ACS National Meeting of the American Chemical Society, Chicago, IL, August 22-27, paper INOR 461 (1993).
8. Heiney PA, Vaughan GBM, Strongin RM, Brard L, Smith III AB, Stephens PW, Liu D, Wudl F, Suzuki T, Li C, Khemani KC. Structure and Orientational Order in C₆₁H₂. MRS National Meeting of the Materials Research Society, San Francisco, CA, April 12-16, paper S4.4 (1993).
9. Strongin RM, Smith III AB, Brard L, Furst GT, Chupa J, Xu S, Fischetti RF, McCauley JP, Blaisie JK, Romanow JW. Fullerene Cyclopropanes and Oxides. Structure Determination and Self-Assembled Monolayers. 33rd National Organic Chemistry Symposium, Bozeman, MT, June 13-17, abstract B-88 (1993).
10. Smith III AB, Strongin RM, Brard L, Furst GT, Romanow WJ, Owens KG King RC. Fullerene Cyclopropanes and Oxides: Structure Determination and Derivatives. MRS National Meeting of the Materials Research Society, Boston, MA, November 29-December 3, paper G7.7 (1993).
11. Brard L, Silver H, Hodgman D. Misoprostol Gel versus Oxytocin for Induction of Labor at Term-A Double Blinded Randomized Controlled Study. Women and Infants Hospital/Brown Medical School, Providence, RI. Resident Research Day, Providence RI, May 2002.
12. Ribaud SE, Brard L, Gordinier ME, Moore RG, Gajewski WH, Granai CO. Primary Invasive Vaginal Cancer: A Retrospective Cohort Study of Thirty-Seven Patients. Women and Infants Hospital/Brown Medical School, Providence, RI. Resident Research Day, Providence RI, June 4, 2003.
13. Strubel-Lagan SL, Brard L, Gordinier ME, Phipps MG, Garrett AP, Granai CO. The Effect of Total Parenteral Nutrition on the Survival of Terminally Ill Ovarian Cancer Patients. Women and Infants Hospital/Brown Medical School, Providence, RI. Resident Research Day, Providence RI, June 4, 2003.
14. Brard L, Swamy N, Granai CO. Anti-Proliferative Effects of Iron Chelators in Gynecologic Cancer Cell Lines. 23rd New England Association of Gynecologic Oncologist Annual Meeting, Prout's Neck, ME, June 6-8, 2003.
15. Brard L, Swamy N, Granai CO. Combined Activity of Iron Chelators and Vitamin D Compounds Against Ovarian Cancer Cell Lines. 23rd New England Association of Gynecologic Oncologist Annual Meeting, Prout's Neck, ME, June 6-8, 2003.

16. Swamy N, Brard L, Granai CO. Anti-Proliferative Activity of Iron Chelators in Tandem with Vitamin D Analogs Against an Ovarian Cancer. 12th Workshop on Vitamin D, Maastricht, The Netherlands, July 6-10, 2003.
17. Brard L, Swamy N, Granai CO. Combined Activity of Iron Chelators and Vitamin D Compounds Against Ovarian Cancer Cell Lines. 1st Annual COBRE Center in Cancer Research & Symposium, Providence, RI, July 31, 2003.
18. Dussault L, Furigay P, Rodriguez CH, Brard L, Brown AK, Swamy N. Iron Chelators Diethylene triamine pentaacetic Acid (DTPA) and Deferoxamine (DFO) Inhibit Endothelial Cell Proliferation and Angiogenesis. 11th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, October 21, 2003.
19. Brard L, Swamy N, Granai CO. Combined Activity of Iron Chelators and Vitamin D Compounds Against Ovarian Cancer Cell Lines. 11th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, October 21, 2003.
20. Rodriguez CH, Furigay P, Brard L, Brown AK, Swamy N. Iron Chelators Inhibit Proliferation of Prostate Cancer Cells and Induce Apoptosis. 11th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, October 21, 2003.
21. Brard L, Swamy N, Granai CO. Combined Activity of Iron Chelators and Vitamin D Compounds Against Ovarian Cancer Cell Lines. 35th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, February 7-11, 2004.
22. Moore RG, Granai CO, Robison K, Brard L, Gajewski WH, Gordinier ME, Steinhoff M. Inguinal Sentinel Node Dissection Versus Standard Inguinal Node Dissection in Patients with Vulvar Cancer: A Comparison of the Size of Metastasis Detected in Inguinal Lymph Nodes. 35th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, February 7-11, 2004.
23. Brard L, Strubel-Lagan SL, Gordinier ME, Phipps MG, Weitzen S, Garrett AP, Granai CO. The Effect of Total Parenteral Nutrition on the Survival of Terminally Ill Ovarian Cancer Patients. 35th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, February 7-11, 2004.
24. Furigay P, Rodriguez CH, Brard L, Swamy N. Iron Chelators Deferoxamine (DFO) and Diethylenetriaminepentaacetic Acid (DTPA) Inhibit Endothelial Cell Proliferation and Angiogenesis. Eastern Society for Pediatric Research (ESPR) Annual Meeting, Old Greenwich, CT, March 26-28, 2004.
25. Furigay P, Rodriguez CH, Brard L, Swamy N. Iron Chelators Deferoxamine (DFO) and Diethylenetriaminepentaacetic Acid (DTPA) Inhibit Endothelial Cell Proliferation and Angiogenesis. Pediatric Academic Societies (PAS) Annual Meeting, San Francisco, CA, May 1-4, 2004.
26. Brard L, Gajewski WH, Moore RG, Granai CO, Gordinier, ME. Recurrent Squamous Cell Carcinoma of the Vulva: Analysis of Disease Free Interval Predictors. 24th Annual Meeting of the New England Association of Gynecologic Oncologists, Chatham, MA, June 11-13, 2004.
27. Brown AK, Swamy N, Rodriguez CH, Brard L, Granai CO. Mechanism of Apoptosis in Ovarian Cancer Cells Treated with Iron Chelators. 24th Annual Meeting of the New England Association of Gynecologic Oncologists, Chatham, MA, June 11-13, 2004.
28. Robison K, Moore RG, Granai CO, Brard L, Gajewski WH, Gordinier ME, Steinhoff, M. Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes. 24th Annual Meeting of the New England Association of Gynecologic Oncologists, Chatham, MA, June 11-13, 2004.
29. Brown AK, Swamy N, Rodriguez CH, Brard L, Granai CO. Mechanism of Apoptosis in Ovarian Cancer Cells Treated with Iron Chelators. 12th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, October 21, 2004.
30. Restivo A, Brard L, Granai CO, Swamy N. Antiproliferative Effect of Mimosine in Ovarian Cancer. 12th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, October 28, 2004.
31. Brard L, Brown AK, Moore RG, Gass J, Granai CO, Swamy N. Deferoxamine (DFO) and Diethylenetriaminepentaacetic Acid (DTPA) Inhibit Endothelial Cell Proliferation and Angiogenesis. 58th Annual Cancer Symposium of the Society of Surgical Oncology, Atlanta, GA, March 2-7, 2005.

32. Brard L, Brown AK, Moore RG, Gass J, Granai CO, Swamy N. Iron Chelators Induce Apoptosis in Prostate Cancer Cells. 58th Annual Cancer Symposium of the Society of Surgical Oncology, Atlanta, GA, March 2-7, 2005.
33. Pirie-Shepherd S, Folkman J, Brard L, Granai CO, Swamy N. Anti-Tumorigenic Activity of Vitamin D-binding Protein is Mediated by the Inhibition of Angiogenesis. 58th Annual Cancer Symposium of the Society of Surgical Oncology, Atlanta, GA, March 2-7, 2005.
34. Brard L, Ribaldo SE, Swamy N, Gordinier ME, DiSilvestro PA, Moore RG, Granai CO. Primary Invasive Vaginal Cancer: A Retrospective Cohort Study of Thirty-Seven Patients. 58th Annual Cancer Symposium of the Society of Surgical Oncology, Atlanta, GA, March 2-7, 2005.
35. Brard L, Chibwasha C, Swamy N, Granai CO. Exploring the Religious/Spiritual Needs of Gynecologic Cancer Patients and their Views on the Role their Physicians Should Take in Meeting Those Needs. 36th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, Miami Beach, FL, March 19-23, 2005.
36. Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in gynecologic cancer cell lines. Women and Infants Hospital/Brown Medical School, Providence, RI. Research Paper Day, Providence RI, May 27, 2005.
37. Robison K, Shafer A, Brard L, Brown AK, DiSilvestro P, Gordinier M, Granai CO, Steinhoff M, Moore RG. Long term follow-up of patients with stage I/II vulvar malignancies evaluated with sentinel lymph node dissections. 25th Annual Meeting of the New England Association of Gynecologic Oncologists, Bretton, NH, June 10-12, 2005.
38. Robison K, Granai CO, Brard L, Brown AK, Steinhoff M, Moore RG. One year follow-up of patients treated with sentinel lymph node biopsy alone for squamous cell carcinoma of the vulva. 25th Annual Meeting of the New England Association of Gynecologic Oncologists, Bretton, NH, June 10-12, 2005.
39. Restivo A, Brard L, Granai CO, Swamy N. Antiproliferative Effect of Mimosine in Ovarian Cancer. 25th Annual Meeting of the New England Association of Gynecologic Oncologists, Bretton, NH, June 10-12, 2005.
40. Chibwasha C, Swamy N, Granai CO, Moore RG, Brard L. Exploring the Religious/Spiritual Needs of Gynecologic Cancer Patients and their Views on the Role their Physicians Should Take in Meeting Those Needs. 13th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, September 29, 2005.
41. Weitzen S, Strubel-Lagan SL, Phipps MG, Swamy N, Moore RG, Granai CO, Brard L. The Effect of Total Parenteral Nutrition on the Survival of Terminally Ill Ovarian Cancer Patients. 13th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, September 29, 2005.
42. Brard L, Ribaldo SE, Weitzen S, Swamy N, Moore RG, Granai CO. Primary Invasive Vaginal Cancer: A Retrospective Cohort Study of Thirty-Seven Patients. 13th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, September 29, 2005.
43. Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of Angiogenesis by Vitamin D-binding Protein: Characterization of Antiendothelial Activity of DBP-maf. 13th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, September 29, 2005.
44. Kalkunte S, Brard L, Dizon DS, Swamy N. Benzyl Isothiocyanate (BITC) Induces Apoptosis in Ovarian Carcinoma. 13th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, September 29, 2005.
45. Moore R, Brown AK, Brard L, DiSilvestro P, Miller C, Allard J, Qudus M, Granai CO. Utility of a Novel Serum Tumor Marker HE4 versus CA-125 in Patients with Endometrial Cancer. 37th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, Palm Springs, California, March 22-26, 2006.
46. Weitzen S, Hughes T, Moore R, Brard L, Granai CO, DiSilvestro P. Does regular medical care improve chances of early detection of epithelial ovarian cancer? 37th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, Palm Springs, California, March 22-26, 2006.
47. McCourt C, Kalkunte S, Strongin R, Alpturk O, Singh R, Gurel V, Zhitkovich A, Granai C, Brard L. Iron salophene is a potent inducer of apoptosis in ovarian cancer. 26th Annual Meeting of the New England Association of Gynecologic Oncologists, Manchester, VT, June 9-11, 2006.

48. Robison K, Singh RK, Kalkunte S, Brard L. 3-Bromoacetoxy Vitamin D3 (B3CD) inhibits growth of pancreatic cancer cells by inducing apoptosis. 14th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, November 9, 2006.
49. Singh RK, Lieb C, Kim KK, Lange TS, Singh AP, Brard L. Indole-ethyl-isothiocyanates as potent antiproliferative agents. 14th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, November 9, 2006.
50. Kim KK, Singh RK, Lange TS, Brard L. Lipophilic iron-chelators as antiproliferative agents in a human ovarian cancer cell line. 14th Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, November 9, 2006.
51. Fuchs K, Brard L, Hodgman D, Silver H. Prostaglandin E1 gel vs. Oxytocin for induction of labor at term. *Am J Obstet Gynecol* 195(6): S101 abstract (2006).
52. Brard L, Singh RK, Kim KK, Lange TS. 3-Bromoacetoxy-Calcidiol (B3CD) inhibits growth of ovarian cancer cells by inducing apoptosis and inhibiting angiogenesis. 9th International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Basic and Clinical Cancer Research, San Diego, CA, Feb 1-3, 2007.
53. Brard L, Singh RK, Kim KK, Lange TS. Anti-endothelial and Antiangiogenic Properties of Benzyl isothiocyanate (BITC) and Phenethyl isothiocyanate (PEITC). 9th International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Basic and Clinical Cancer Research, San Diego, CA, February 1-3, 2007.
54. Brard L, Singh RK, Kim KK, Lange TS. Iron Chelators Deferoxamine (DFO) and Diethylenetriaminepentaacetic Acid (DTPA) Inhibit Endothelial Cell Proliferation and Angiogenesis. 9th International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Basic and Clinical Cancer Research, San Diego, CA, February 1-3, 2007.
55. Brard L, Robison K, Singh R, Kim K, Lange T. A Novel Non-Hypercalcemic Vitamin D Derivative in the Treatment of Ovarian Cancer in Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Poster Abstracts. *J Womens Health*;16(8):1095-1107 (2007).
56. Brard L, Singh RK, Kalkunte SK, Lange TS, Kim K, Dizon DS. Isothiocyanates inhibit growth of ovarian cancer cells by inhibiting epidermal growth factor receptor signaling and c-Myc expression. 38th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007.
57. Brard L, Singh RK, Lieb C, Kim K, Lange TS, Singh AP. Indole-ethyl-isothiocyanates as potent antiproliferative agents. 38th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007.
58. Robison KM, Singh RK, Kalkunte S, Lieb C, Kim K, Lange TS, Brard L. Isothiocyanates are active in the treatment of ovarian cancer in an animal model. 38th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007.
59. McCourt C, Young, Schwartz J, Young W, DiSilvestro P, Brard L, Tejada-Berges T, Bradley A, Dizon D. Factors associated with response to taxanes as a later-line treatment of recurrent ovarian cancer. 38th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007.
60. Restivo A, DiSilvestro P, Moore R, Tejada-Berges T, Brard L, Bandera C, Granai CO, Myers T, Dizon D. Preliminary findings from a phase II study of bortezomib and irinotecan for advanced cervical cancer. 38th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007.
61. Moore R, Robison K, Brard L, Tejada-Berges T, DiSilvestro P, Steinhoff M, Granai CO. Sentinel lymph node dissection alone with conservative management in patients with squamous cell carcinoma of the vulva. 38th Annual Meeting on Women's Cancer, Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007.
62. Dorf L, Kalkunte S, Singh R, Brard L, Saulnier-Sholler G. Sulforaphane is cytotoxic to neuroblastoma both in vitro and in vivo. Pediatric Academic Societies (PAS) Annual Meeting, Toronto, Canada, May 5-8, 2007.
63. Saulnier Sholler G, Dorf L, Straub J, Brard L, Nishi R. Nifurtimox is cytotoxic to catecholamine-containing cells which is enhanced by ascorbic acid and suppresses neuroblastoma growth in vivo. Pediatric Academic Societies (PAS) Annual Meeting, Toronto, Canada, May 5-8, 2007.

64. Robison K, Brard L, DiSilvestro P, Steinhoff M, Granai CO, Moore R. Sentinel lymph node dissection alone with conservative management in patients with squamous cell carcinoma of the vulva: A long-term follow-up. 27th Annual Meeting of the New England Association of Gynecologic Oncologists, Kennebunkport, ME, June 8-10, 2007.
65. Robison K, Singh R, Kim K, Lange T, Granai CO, Brard L. A Novel Non-Hypercalcemic Vitamin D Derivative in the Treatment of Ovarian Cancer. 27th Annual Meeting of the New England Association of Gynecologic Oncologists, Kennebunkport, ME, June 8-10, 2007. **First Prize Paper**.
66. Matthews C, Restivo AM, Raker C, Moore R, Brard L, Tejada-Berges T, Granai CO, DiSilvestro P. Perception and Willingness of Cancer Patients to take part in Clinical Trials: How can we increase accrual? 27th Annual Meeting of the New England Association of Gynecologic Oncologists, Kennebunkport, ME, June 8-10, 2007.
67. Simpson MC, Sung J, DiSilvestro P, Brard L, Granai CO. Comparison of Frozen Section to Final Pathology for LMP tumors of the Ovary. 27th Annual Meeting of the New England Association of Gynecologic Oncologists, Kennebunkport, ME, June 8-10, 2007.
68. Singh AP, Singh RK, Kalkunte SS, Nussbaum R, Kim K, Jin H, Torres MS, Brard L, Vorsa N. Cranberry Proanthocyanidins Sensitize Ovarian Cancer Cells to Platinum Drug. 234th National Meeting of the American Chemical Society, Boston, MA, August 17-21, paper AGFD 140 (2007). **Press release** (CBS News and Forbes).
69. Brard L, Robison K, Singh R, Kim K, Lange T. A Novel Non-Hypercalcemic Vitamin D Derivative in the Treatment of Ovarian Cancer. Fourth Annual NIH Interdisciplinary Women's Health Research Symposium, Rockville, MD, November 13-15, 2007.
70. Robison K, Kim KK, Singh R, Lange T, Granai CO, Brard L. The use of a vitamin D derivative in a mouse xenograft ovarian cancer model. 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, March 9-12, 2008.
71. McCourt C, Dessie S, Dizon DS, Young M, Brard L, Legare R, Sakr B, DiSilvestro P. Platinum-free, taxane-free, or treatment-free interval: Which predicts response to taxane therapy as third- or later-line treatment? 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, March 9-12, 2008.
72. Koto K, Brard L, Bosenberg M, Dorf L, Illenye S, Singh R, Kim KK, Saulnier Sholler G. Antitumor activity of Nifurtimox and MT-19C alone and in combination in medulloblastoma *in vitro* and *in vivo*. 99th American Association of Cancer Research (AACR) Annual Meeting, San Diego, CA, April 12-16, 2008.
73. Saulnier Sholler G, Ferguson W, Brard L, Johnson G, Heath B, Bingham P, Taka A, Kamen B, Homans A. A phase I study of nifurtimox in patients with relapsed/refractory neuroblastoma. 44th American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 30-June 3, 2008.
74. Stuckey AR, Lange TS, Robison K, Kim KK, Singh RK, Brard L. Effect of B3CD, a Novel Vitamin D Derivative in an Ovarian Cancer Animal Model. 28th Annual Meeting of the New England Association of Gynecologic Oncologists, Chatham, MA, June 13-15, 2008.
75. Saulnier Sholler G, Ferguson W, Brard L, Johnson G, Heath B, Bingham P, Taka A, Kamen B, Homans A. A phase I study of nifurtimox in patients with relapsed/refractory neuroblastoma. *J Clin Oncol* 26: (May 20 suppl; abstr. 2561) (2008).
76. Singh RK, Lange TS, Kim K, Singh AP, Hopson R, Vorsa N, Brard L. ChemInform Abstract: Synthesis of Bicyclic Aryl Thiazolines with Selective Anti-proliferative Effects on Human Cancer Cell Lines. *Chem Inform* 39(28), (July 8) (2008).
77. Robison K, Kim KK, Singh R, Lange T, Granai CO, Brard L. The use of a vitamin D derivative in a mouse xenograft ovarian cancer model. *Gynecol Oncol* 108 (2008) S68 (abstract).
78. McCourt C, Dessie S, Dizon DS, Young M, Brard L, Legare R, Sakr B, DiSilvestro P. Platinum-free, taxane-free, or treatment-free interval: Which predicts response to taxane therapy as third- or later-line treatment? *Gynecol Oncol* 108 (2008) S134 (abstract).

79. Kim K, Singh RK, Singh AP, Brard L. Cranberry Extracts (PAC-1) Display Cytotoxic Activity by JNK/p38 Activation in SKOV-3 and Possess Anti-Angiogenic Activity. Chemistry in Cancer Research, Joint conference presented by the American Association for Cancer Research (AACR) and the American Chemical Society, New Orleans, LA, February 8-11, 2009.
80. Singh RK, Kim K, Lange TS, Saulnier-Sholler G, Brard L. Coumarin Derivative (RKS262) Causes Selective Cytotoxicity, Pro-Apoptotic MAPKs and Specific BCL2 Signaling and Cell-cycle Arrest in Ovarian Cancer Cells. Chemistry in Cancer Research, Joint conference presented by the American Association for Cancer Research (AACR) and the American Chemical Society, New Orleans, LA, February 8-11, 2009.
81. Dorf L, Brard L, Koto K, Illenye S, Ashikaga T, Singh R, Kim K, Saulnier Sholler G. Increased Cytotoxicity with Nifurtimox and Rapamycin Combination Therapy in Neuroblastoma. 100th American Association of Cancer Research (AACR) Annual Meeting, Denver, CO, April 18-22, 2009.
82. Singh AP, Singh RK, Kim KK, Shah S, Brard L, Vorsa N. LC-MS-MS quantification of cyclophosphamide in SMSKCNr cells in absence and presence of cranberry proanthocyanidins. Eastern Analytical Symposium, Somerset NJ, November 16-19, 2009.
83. Stuckey AR, Kim KK, Singh RK, Fischer A, Miller D, Hillenmeyer S, Ritz A, Raphael B, Brodsky AS, Brard L. Developing an Integrated Genomic Approach to Explore the Antitumor Activity of Vitamin D and Derivatives to Treat Ovarian Cancer. 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, March 14-17, 2010.
84. Olson C, Dizon D, Stuckey A, MacLaughlan S, Sakr B, Brard L, Legare R. Outcomes for Women with Cancer Receiving Bevacizumab in an Academic Women's Oncology Program. 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, March 14-17, 2010.
85. Horowitz N, Olawaiye A, Growdon W, Borger D, Dizon D, Brard L, Matulonis U, MacNeill K, Roche M, Krasner C. Phase II Trial of Tarceva (erlotinib) in Women with Squamous Cell Carcinoma of the Vulva. 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, March 14-17, 2010.
86. MacLaughlan S, Fischer A, Kristjansdottir K, Ritz A, Raphael B, Steinhoff M, Brodsky A, Brard L. Genetics of Primary and Metastatic Ovarian Cancer. 101st American Association of Cancer Research (AACR) Annual Meeting, Washington, DC, April 17- 21, 2010.
87. Stuckey AR, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Raphael BJ, Brard L, Brodsky AS. Developing an Integrated Genomic Approach to Explore the Antitumor Activity of Vitamin D and Derivatives to Treat Ovarian Cancer. 30th Meeting - New England Association of Gynecologic Oncologists, Booth Bay, ME, Jun 11-13, 2010.
88. Kristjansdottir K, Choi JS, Kim KK, Singh RK, Lange TS, Granai CO, Brard L. 7-Methyl Indole Ethyl Isothiocyanate- A Novel Cytotoxic Agent for Endometrial Cancer. 30th Meeting of the New England Association of Gynecologic Oncologists, Booth Bay, ME, Jun 11-13, 2010. **First Prize Paper.**

ABSTRACTS PUBLISHED WHILE AT SIU

89. Kristjansdottir K, Singh RK, Kim K, Lange T, Brard L. 7-Methyl indole ethyl isothiocyanate: A novel cytotoxic agent for endometrial cancer. 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, March 6-9, 2011. *Gynecol Oncol*, **2011**;120(S1):S41 .
90. Brodsky AS, Miller DH, Douglass E, Vang S, Fischer A, MacLaughlan S, Kristjansdottir K, Steinhoff M, Brard L. Integrated Genomics Reveals Candidate Metastatic Drivers of Ovarian Cancer. CSHL Meeting - The Biology of Cancer: Microenvironment, Metastasis & Therapeutics, Cold Springs Harbor, NY, April 26-30, 2011.
91. Miller DH, Douglass E, Lynch K, Fischer A, Comisar L, Hillenmeyer S, Brard L, Brodsky AS. LXR Ligands Inhibit Cytotoxic Drugs in 2D and Inhibit Growth in 3D Culture: Conflicting Implications for Drug Response and Tumorigenicity. CSHL Meeting - The Biology of Cancer: Microenvironment, Metastasis & Therapeutics, Cold Springs Harbor, NY, April 26-30, 2011.
92. Ayyagari V, Brard L. Studies on anti-tumor effects of Bithionol on ovarian cancer cell lines. American Association of Cancer Research (AACR) Annual Meeting, Washington, DC, April 6-10, 2013.

93. Thomson JA, Radtke S, Groesch K, Diaz-Sylvester PL, Brard L. Diagnostic Utility of Culdocentesis in Patients with a Suspicious Adnexal Mass. Simmons Cancer Institute at SIU, Basic and Translational Research Symposium. Springfield, IL, November 7, 2015.
94. Thomson JA, Radtke S, Groesch K, Diaz-Sylvester PL, Wilson T, Delfino K, Brard L. Diagnostic Utility of Culdocentesis in Patients with a Suspicious Adnexal Mass. 26th Annual Trainee Research Symposium. Springfield, IL, April 28, 2016.
95. Colditz GA, Brard L, James A, Jenkins W, Steward D, Izadi S, Fogleman A. Addressing Rural Cancer Health Disparities: A Siteman-SIUSM Partnership. 2016 NCI Partnership to Advance Cancer Health Equity (PACHE) Investigators Meeting. Rockville, MD, June 12, 2016.
96. Zahnd WE, McQueen A, Lobb R, Diaz-Sylvester P, Brard L. Rural-Urban and Access to Care Differences in Cervical Cancer Stage at Diagnosis. Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. Fort Lauderdale, FL, September 25-28, 2016.
97. Ayyagari VN, Wang X, Brard L. Studies on role of acyl-CoA cholesterol acyltransferase (ACAT) expression in ovarian/endometrial cancer. AACR Annual Meeting 2017, Washington, DC, April 1-5, 2017.
98. Brard L, Hyon KS, Izadi SR, Diaz-Sylvester P, Zahnd WE, Colditz GA. Rural-Urban Variation in Surgical Treatment, Lymph Node Examination, and Adequate Lymphadenectomy for Endometrial Cancer Patients. 2017 Rural Cancer Control: Challenges and Opportunities Meeting. Memphis, TN, May 4-5, 2017.
99. Colditz GA, James A, Jenkins W, Steward D, Izadi SR, Fogleman A, Brard L. Addressing Rural Cancer Health Disparities: A Siteman-SIUSM Partnership. 2017 Rural Cancer Control: Challenges and Opportunities Meeting. Memphis, TN, May 4-5, 2017.
100. Candel S. Karr M, Brard L, Thomson A, Groesch K, Welge M, Bushell C, Zhu R, Auvil L, Miao R, Braundmeier-Fleming A. Microbial Profiles and Tumor Markers from Culdocentesis: a Novel Screening Method for Epithelial Ovarian Cancer. 2017 ACOG Annual Clinical and Scientific Meeting, San Diego, CA, May 6-9, 2017.

BOOK CHAPTERS

1. Neumann DA, Fischer JE, Copley JRD, Heiney PA, Rush JJ, Strongin RM, Brard L, Smith III AB. Neutron Scattering Studies of $C_{61}H_2$ in *Science and Technology of Fullerene Materials*, edited by Bernier P, Ebbesen TW, Bethune TS, Metzger RM, Chiang LY, Mintmire JW. Mater. Res. Soc. Proc. 359, Pittsburgh, PA. p. 537, (1995).
2. Neumann DA, Huang Q, Copley JRD, Fischer JE, Heiney PA, Strongin RM, Brard L, Smith III AB. A Neutron Diffraction Study of the 6,5-Annulene Isomer of $C_{61}H_2$. Proc.-Electrochem. Soc., 95-10 *Recent Advances in the Chemistry and Physics of Fullerenes and Related Materials*, R. S. Ruoff and K. M. Kadish, Eds., The Electrochemical Society, Pennington, N. J., 791-797 (1995).
3. Meingast C, Roth G, Kappes MM, Michel RH, Stoermer C, Brard L, Heiney PA, Fischer JE, Smith III AB, Strongin RM. Orientational glass transitions in the fullerene derivatives $C_{60}O$ and $C_{61}H_2$. Phys. Chem. Fullerenes Deriv., Proc. Int. Wintersch. Electron. Prop. Novel Mater., H. Kuzmany, Ed., World Scientific: Singapore, 167-170 (1995).

ORAL PRESENTATIONS

1. Brard L. Misoprostol Gel versus Oxytocin for Induction of Labor at Term-A Double Blinded Randomized Controlled Study. Women and Infants Hospital/Brown Medical School, Providence, RI. Oral presentation, Resident Research Day, Providence RI, May 2002.
2. Brard L. A Brief History of Genetics: Important Developments in the 19th and 20th Centuries. The 17th Annual Ritz Conference. Women and Infants Hospital of RI, Program in Women's Oncology, Providence RI, December 4, 2002.

3. Brard L, Slocomb MA, Crager J, Kellerman F, Swanson R. Successful On-Line Searching Using the Brown, Lifespan, and WIH Library Resources. Grand Rounds, Women and Infants Hospital of Rhode Island, Providence RI, January 2, 2003.
4. Brard L. Screening the Cervix and an ER Case: A Gynecologist's Perspective. University of Rhode Island, South Kingston, RI, May 6, 2003.
5. Brard L, Swamy N. Granai CO. Anti-proliferative effects of Iron Chelators in Gynecologic Cancer Cell Lines. 23rd New England Association of Gynecologic Oncologist Annual Meeting, Prout's Neck, ME, June 6-8, 2003.
6. Brard L, Swamy N. Granai CO. Combined Activity of Iron Chelators and Vitamin D Compounds Against Ovarian Cancer Cell Lines. 23rd New England Association of Gynecologic Oncologist Annual Meeting, Prout's Neck, ME, June 6-8, 2003.
7. Granai CO, Brard L, Moore RG. Anything Worth Doing is Worth Doing Lousy. 92nd Annual Meeting of the American Gynecologic Club. Providence, RI, October 16-19, 2003.
8. Tejada-Bergés T, Brard L, Brown A, Wiggins D, Legare R, Dizon D. Of Surgeons, Sturgeons and Other Forced Rhymes. Annual Contemporary Issues in Healthcare. The 18th Annual Ritz Conference, Roger Williams Park, Providence, RI, December 10, 2003.
9. Brard L, Gajewski WH, Moore RG, Granai CO, Gordinier ME. Recurrent Squamous Cell Carcinoma of the Vulva: Analysis of Disease Free Interval Predictors. 24th Annual Meeting of the New England Association of Gynecologic Oncologists, Chatham, MA, June 11-13, 2004.
10. Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in gynecologic cancer cell lines. Women and Infants Hospital/Brown Medical School, Providence, RI. Oral presentation, Research Paper Day, Providence RI, May 27, 2005.
11. Brard L. Ovarian Cancer: Diagnosis and Treatment. Grand Rounds, Milford Regional Hospital, Milford, MA, October 24, 2005.
12. McCourt C, Restivo A, Brown AK, Brard L, Tejada-Bergés T, Dizon D, Moore RG, Bandera C, Wiggins D, Granai CO. Dementia Imaginarius. The 20th Annual Ritz Conference, Crowne Plaza Hotel, Warwick, RI. November 23, 2005.
13. Brard L. Small Molecules in Cancer Therapy: A Journey from Iron Chelators to Vitamin D Derivatives. The Department of Molecular Pharmacology, Physiology & Biotechnology Seminar Series. Brown University, RI. December 18, 2005.
14. Brard L. (Invited Speaker) Colorectal Cancers Metastasis to Gynecologic Organs: Current Approach. Current Therapy in Colon and Rectal Cancer, 2nd Annual Symposium, Crowne Plaza Hotel Providence-Warwick, RI, March 18-19, 2006.
15. Brard L. (Invited Lecturer). Small Molecules in Cancer Therapy: Iron Salophene as an Anti-Ovarian Cancer Drug. IMSD Program. Department of Chemistry, Louisiana State University, LA, April 28, 2006.
16. Brard L. (Guest Speaker). Iron Chelators in the Treatment of Ovarian Cancer, OCRF Brunch Benefit, Johnston, RI, May 27, 2006.
17. Brard L. The Synthesis and Development of New Anti-cancer Agents. COBRE CCRD Seminar Series, Liver Research Center, Providence RI, December 21, 2006.
18. Brard L. (Guest Speaker). Natural Product Derivatives for the Treatment of Neuroblastoma. Developments in Neuroblastoma Research Symposium, Vermont Cancer Center, University of Vermont, Burlington VT, March 15-16, 2007.
19. Brard L. (Invited Lecturer). Early Drug Discovery in an Academic Setting: Development of Natural Product Derivatives for the Treatment of Solid Tumors. Grand Rounds, Department of Obstetrics and Gynecology, University of Vermont, Burlington VT, October 2, 2007.

20. Brard L. (Invited Speaker). Vitamin D Derivatives for the Treatment of Neuroblastoma and Medulloblastoma. Neuroblastoma and Medulloblastoma Working Meeting (precursor to the NMTRC), New York, NY, January 28, 2008.
21. Brard L. (Invited Lecturer). Vitamin D Derivatives for the Treatment of Solid Tumors. University of Utah Huntsman Cancer Institute, Salt Lake City, UT, May 21, 2008.
22. Brard L. (Invited Speaker). Discovery of the first Ergocalciferol derived vitamin D receptor independent true non-hypercalcemic anti-cancer agent. University of Connecticut, Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, June 24, 2010.

ORAL PRESENTATIONS GIVEN WHILE AT SIU

23. Brard L. (Invited Speaker). Ovarian Cancer: From Drug Discovery to Genomics. Department of Physiology, Southern Illinois University School of Medicine, Carbondale Campus, Carbondale, IL, March 10, 2011.
24. Brard L. (Invited Speaker). Oxidative Stress and Cancer Drug Discovery. Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, April 15, 2011.
25. Brard L. Ovarian Cancer Overview. Grand Rounds, Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine. Springfield, IL, April 22, 2011.
26. Brard L. Discovery of the First Ergocalciferol Derived Vitamin D Receptor Independent True Non-Hypercalcemic Anti-Cancer Agent. Simmons Cancer Institute at SIU. Springfield, IL, August 25, 2011.
27. Brard L. Small Molecule Anti-Cancer Drug Discovery in the Academic Setting. Simmons Cancer Institute at SIU, Research Symposium. Springfield, IL, October 29, 2011.
28. Brard L. Gynecologic Cancer in the Pregnant Patient. Grand Rounds, Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine. Springfield, IL, December 13, 2011.
29. Brard L. HPV and Cervical Cancer. Annual Simmons Cancer Institute Cancer at SIU Symposium, February 1, 2012.
30. Brard L. Intraperitoneal Treatment for Ovarian Cancer. Memorial Medical Center, Springfield, IL, May 9, 2012.
31. Brard L. Gynecology Oncology. Montgomery County Cancer Association. Lincoln Land Community College, Litchfield, IL, May 12, 2012.
32. Brard L. (Invited Speaker). Cervical Cancer Screening for Primary Care Providers. Annual Simmons Cancer Institute at SIU Cancer Symposium. Springfield, IL, February 7, 2014.
33. Brard L. (Invited Speaker). Cervical Cancer Screening Guidelines for the Primary Care Practitioner. Updates in Primary Care. John A. Logan College, Carterville, IL, May 7, 2014.
34. Brard L. (Invited Speaker). Drug Repositioning in the Treatment of Ovarian Cancer. Simmons Cancer Institute at SIU, Basic and Translational Research Symposium. Springfield, IL, November 7, 2015.
35. Brard L. (Introductory Speaker). 1st Rural Cancer Disparities Retreat. Simmons Cancer Institute at SIU. Springfield, IL, December 11, 2015.
36. Brard L. (Invited Speaker). Ovarian Cancer Biomarker and Drug Discovery in an Academic Setting. University of Illinois, Springfield Campus (UIS), Springfield, IL, March 25, 2016.
37. Brard L. (Invited Speaker). Update on Gynecologic Cancers. Updates in Primary Care. John A. Logan College, Carterville, IL, May 4, 2016.
38. Brard L. (Invited Speaker). Updates on HPV and Cervical Cancer. Simmons Cancer Institute at SIU, Springfield, IL, May 25, 2016.

39. Brard L. (Invited Speaker). "It Can't Happen to Me: Uterine and Cervical Cancers." Gynecologic Cancer Awareness Seminar. Memorial Medical Center, Springfield, IL, September 26, 2016.
40. Brard L. (Introductory Speaker). Bridging the Gap: Exploring Rural-Urban Cancer Disparities: 3rd Rural Cancer Disparities WUSTL Siteman – SIUSM Partnership Retreat. Simmons Cancer Institute at SIU. Springfield, IL, March 17, 2017.
41. Brard L. (Invited Speaker). Cervical Cancer Screening Guidelines for Primary Care Providers. Illinois Women's Health Conference, Illinois Department of Public Health, Springfield, IL, March 23-24, 2017.
42. Brard L. (Introductory Speaker). The 4th Rural Cancer Disparities WUSTL Siteman – SIUSM Partnership Retreat. Simmons Cancer Institute at SIU. Springfield, IL, October 27, 2017.
43. Brard L. (Invited Speaker). TeleGynecologic Oncology: Update on Ovarian and Endometrial Cancer. SIU School of Medicine, Springfield, IL, February 23, 2018.

MEDIA INTERVIEWS

1. WSIU, July 5, 2016. WSIU InFocus: Cancer Research Symposium. <http://news.wsiu.org/post/wsiu-infocus-cancer-research-symposium#stream/0>
2. WTAX, September 6, 2016. Ask The Expert - Ovarian Cancer and Uterine Cancer. [http://www.askmemorial.org/.
http://www.disasterradio.net/audio/ASK/asktheexpert0906.mp3](http://www.askmemorial.org/.http://www.disasterradio.net/audio/ASK/asktheexpert0906.mp3)
3. Interview for Aspects (SIU School of Medicine's Quarterly Magazine), August 11, 2017. Spreading the word about HPV's Highly Protective Vaccine.